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PREFACE 
 
What impact does dietary exposure to aflatoxins has on hepatocellular carcinoma 
in India? Assessing the connection between aflatoxin contamination in the diets, 
Hepatitis B virus infection and liver cirrhosis through Hospital based study in 
Andhra Pradesh, India   
 
Chronic exposure to aflatoxins was shown to cause impaired growth in children, 
immune suppression and liver cirrhosis, interference in micronutrient metabolism and 
reduced human and animal productivity. Acute severe intoxication can result in death. 
Most importantly, aflatoxin was shown to interact synergistically with Hepatitis B 
virus (HBV) / Hepatitis C virus infection. It increases the risk of hepatocellular 
carcinoma (HCC), one of the most common cancers in the developing countries with 
>400,000 new cases per annum. A joint FAO and WHO committee concluded that 
reduced intake of aflatoxins in HBV endemic places will have a greater impact on 
reducing the incidence of HCC. This requires knowledge on the level of aflatoxin 
exposure in populations, dietary sources of contamination and household dietary 
practices leading to frequent food contamination in order to identify high risk groups 
and to develop preventive interventions to mitigate human exposure to aflatoxins.  
 
Aflatoxins in human body are metabolized by the liver enzymes and produces 
aflatoxin 8,9-epoxide, which reacts with albumin in the liver to form AFB1-albumin 
adducts that are major biomarkers found in peripheral blood. In order to protect human 
health it is important to be able to estimate aflatoxin-albumin adduct in human blood. 
Among many methods available for estimation immunochemical methods are simple, 
cost effective and adaptable to situations in developing countries. Hence this study is 
proposed to assess the aflatoxin exposure in Indian populations using ELISA which 
will lead to the development of preventive interventions to minimize the risk of liver 
disorders and HCC. 
 
This thesis is divided into 9 chapters containing subsections. Chapter 1 and chapter 2 
contains the introduction and review of literature. Chapter 3 contains materials and 
methods for the development of antibodies to detect aflatoxin-albumin adduct in 
human blood samples. Chapter 4 contains Results. Chapter 5 and 6 contains 
discussion, summary and conclusion. Chapter 7 contains references, Chapter 8 
contains appendix and Chapter 9 contains Annexure I, II and Master charts.  
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1. Introduction 
Several naturally occurring toxins produced by microorganisms such as bacteria and 
fungi frequently contaminate food and feed, and pose a serious health risk to 
mammals, fish and poultry (Garcia and Park, 1998; Brown et al., 1998). Of the various 
toxins, mycotoxins produced by the fungi are most frequent contaminants in food and 
feed and are responsible for several food-borne illnesses. Mycotoxins are non-volatile, 
low molecular weight products produced as byproducts during the primary metabolic 
process of the fungi (http://www.moldreporter.org/volno3/mycotoxins). The purpose 
of mycotoxins in fungal growth is not clearly understood, but they are believed to play 
a role in eliminating other microorganisms competing in the same environment and 
help in further invasion of the host tissues. Over 300 mycotoxins are known and they 
are produced by several species of fungi. Most of the mycotoxins of concern are 
produced by three genera: Aspergillus, Penicillium, and Fusarium Stachybotrys and 
Myrothecium (Bilgrami and Choudhary, 1998). However, only some species/strains of 
fungi are capable of producing toxins and such strains are referred as ‘toxigenic 
strains’. Of various mycotoxins, aflatoxins produced by Aspergillus flavus, Aspergillus 
parasiticus are most important and extensive efforts have been made to understand the 
biosynthesis, its ill affects on humans and livestock and management. 
  
Aspergillus flavus and A. parasiticus infest a number of staple crops, spices and 
tree nuts (eg. maize, groundnut, pistachio, cashew nut, chillies, etc) (Brown et al., 
1998). It is saprophytic and grows on a wide variety of substrates including decaying 
plant and animal debris (Payne, 1998). The fungi survive in the soil and warehouses as 
mycelium, conidia, and sclerotia, which resistant harsh conditions and invade crops 
and commodities alike. The fungi produce aflatoxins under favorable temperature, 
humidity and moisture content in the substrate (Sinha, 1998). The primary cause of 
preharvest contamination is growth of spores deposited on the crops by wind currents, 
insect vectors and contact. Post-harvest contamination occurs when storage conditions 
favor germination of spores and mold growth begins when the moisture content of the 
stored grains exceeds 17.5% relative humidity and temperatures exceeds 24°C. Thus 
mycotoxin contamination of feed grains is problematic in years with a dry growing 
season and wet harvest season, and such conditions are common in tropical, sub-
tropical and semi-arid tropical parts of the world.  
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Aflatoxins were first identified in 1960s and they consists a family of toxic 
compounds designated as B1, B2, G1, G2 and M1 (Williams et al., 2004). Aflatoxin 
B1 is the most toxic and best studied of the compounds. The toxic effects include acute 
hepatitis, immunosuppression, and hepatocellular carcinoma (Williams et al., 2004). In 
humans, the risks associated with aflatoxin consumption have been well documented, 
and the International Agency for Research on Cancer (IARC) has designated aflatoxin 
as a human liver carcinogen. For humans, aflatoxin is predominantly perceived as an 
agent promoting liver cancer. Moreover, aflatoxin was shown to act synergistically 
with Hepatitis virus B and C infections and increases the risk of liver cancer by 30 - 60 
times (Groopman, 1993; Henry et al., 2002). In addition, aflatoxins can cause growth 
inhibition and immune suppression in humans and animals. Because of the toxic 
effects the Food Safety regulations have been established with statutory limits of 
aflatoxin in food and feeds for consumption and trade (FAO, 2004). Regulations were 
established to monitor aflatoxins levels in food and feed samples and only those that 
contain zero or levels proscribed by the food safety regulations are allowed for trade 
and consumption (FAO, 2004). However, such procedures are poorly practices in 
developing countries. Thus, health hazards from consumption of aflatoxin-
contaminated foods are much greater in the developing countries than the developed 
countries.  
 
Although aflatoxin contamination is a global problem, it is most widespread in 
developing countries in the tropics. The environment, farming practices, socio-
economic conditions, lack of awareness about the problem, inadequate aflatoxin 
monitoring skills and processing facilities makes the crops and commodities produced 
in these countries highly vulnerable to the contamination (Ortiz et al., 2005; Waliyar et 
al., 2005b). Staple foods such as groundnut, maize, spices like chillies, and several 
edible tree nuts (Brown et al., 1998) grown in developing countries are frequently 
contaminated with aflatoxins and they easily make way into food chain. Most recently 
consumption of aflatoxin-contaminated maize has led to over 100 deaths in Kenya 
(Strosnider et al., 2006). Mandatory analysis of food and feed products are rarely 
followed in developing countries to control human exposure to the aflatoxins 
predisposing populations to the risk of aflatoxin-linked illnesses and even cancer 
(Williams et al., 2004). Information is limited on the individual levels of exposure to 
aflatoxins in Humans. Studies in West Africa showed significant proportion of 
 20
population were exposed to the aflatoxins, which provided a scope to establish 
intervening strategies to reduce the risk of exposure through food and also to estimate 
the risk of cancer (Turner et al., 2005).   
 
Aflatoxin contamination in humans is analyzed through quantitative estimation of 
adducts of aflatoxin B1 (AFB1) that covalently binds to lysine moiety of serum 
albumin [AFB1-lysine (AFB1-lys)]. AFB1-lys in serum fraction serves as quantifiable 
biomarkers to assess the risk of exposure. Although knowledge on the metabolic cycle 
of AFB1 has led to the identification of several biomarkers in blood, urine, feces and 
tissues (Turner et al., 1998) that can be used to monitor the AFB1 exposure, but the 
most well studied biomarker has been the AFB1-lys. It has been shown that AFB1-lys 
concentration in albumin reflects the level of DNA damage in the liver, which is the 
target organ for liver cancer (Skipper and Tannenbaum, 1990). Moreover, AFB1-lys in 
the blood can be estimated up to 20 days or even a month following its formation. 
Most importantly, antibodies can be produced to AFB1-lys that can be conveniently 
used to estimate the AFB1-lys adducts in albumin fraction by enzyme-linked 
immunosorbent assay (ELISA).  
 
ELISA is by far the most widely used serological test for the detection of aflatoxins, 
because of its simplicity, adaptability and sensitivity (Wilson et al., 1998). This is based 
on the reaction between the antigen and antibody that is produced against. 
Immunological recognition is based on the special complement of specific groups of 
the antigen with those of the antibody. Immuno-specificity is recognized through the 
action of the associated enzyme label on a suitable substrate. For the detection of AFB1-
lys, competitive ELISA is used (Waliyar et al., 2005a). In this a known amount of 
AFB1-ovalbumin is adsorbed to the plate surface. Competition is between antibody 
with the toxin present in the albumin sample or in the standard. The antibodies that 
react with AFB1-lys in the sample get neutralized and eliminated. Whereas the 
unbound antibody will bind to the AFB1-ovalbumin coated to the plate. The bound 
antibodies were detected using enzyme labeled anti-species antibody, which provides 
the measurement of the reaction.  
 
This study was planned to standardize the competitive ELISA method for the 
estimation of AFB1-lys in human serum albumin. Recently, polyclonal antibodies for 
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AFB1-lys were produced at the International Crops Research Institute for the Semi-
Arid Tropics (ICRISAT). These antibodies were used to standardize the method and 
the efficacy of these antibodies was validated by comparing with the antibodies 
produced at Columbian University, USA (kindly provided by Dr Regina M. Santella, 
Professor of Environmental Health Sciences, Mailman School of Public Health, 
Columbia University). This method would be useful for assaying the level of aflatoxin 
exposure among Indian population.  
 
Objectives: 
The objectives of this study are:  
? To produce, standardize and validate the polyclonal and monoclonal antibody 
against afaltoxin albumin adduct.  
? To standardize competitive ELISA method for estimating the AFB1-lys in 
serum fraction  
? To do transactional studies to determine aflatoxin exposure by measuring 
aflatoxin biomarker among various liver diseased patients in Hyderabad. 
? To standardize and detect aflatoxin-albumin adduct from Hepatitis B positive 
samples and to detect 249ser mutation of p53 gene using PCR/RFLP. 
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2. Review of Literature 
 
2.1. Mycotoxins 
Many agricultural commodities are vulnerable to attack by a group of fungi that are 
able to produce toxic metabolites called mycotoxins. Mycotoxin contamination in 
crops and commodities are regarded as unavoidable and has been a serious challenge 
to food safety.  
 
Mycotoxins are toxic secondary metabolites of low molecular weight produced by 
certain species of fungi (Chu, 1992). They are usually named on the basis of the 
fungus that produces them. For example, aflatoxin produced by Aspergillus flavus uses 
A for Aspergillus and fla for species flavus along with the word toxin as suffix. There 
are three major genera of fungi that produce mycotoxins: Aspergillus, Fusarium and 
Penicilium. Mycotoxin producing fungi grow on a wide spectrum of crops, food and 
feed and invade at any time during pre-harvest, post-harvest, processing, transport, 
storage and distribution. The growth of storage fungi, and their production of 
secondary metabolites, presents a major problem to agriculture, feed and food 
industries worldwide.  
 
Fungal invasion of stored agricultural products leads to quality loss in many ways: 
unacceptable physicochemical changes in the products such as deterioration of color, 
texture and taste, development of fungal odors (Abramson, 1991; Kaminski and  
Wasowicz, 1991), reduction of seed germination, energy and nutritional loss, 
production of allergens affecting livestock (Flannigan et al., 1991) and formation of 
toxic metabolic products such as mycotoxins. The Food and Agriculture Organization 
(FAO) of the United Nations has reported every year, at least 25% of the world’s food 
crops are contaminated with mycotoxins. 
 
The mycotoxin producing fungi are aerobic and can be both pathogenic to plants 
and/or saprophytic with them. Common members of mycotoxin family include: 
aflatoxin, trichothecenes, zearalenone, fumonisin, ochratoxins and slaframine (Table 
1). The main toxigenic species are A. flavus and A. parasiticus, which produce 
aflatoxins and A. ochraceus for ochratoxins (Abramson, 1998).  
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Table 1. Details of some commonly occurring mycotoxins (Chu, 1995) 
 
Mycotoxins Major producing fungi Typical substrate in 
nature 
Biological effect 
Alternaria mycotoxin 
(AM) 
Alternaria alternata Cereal grains, tomato, 
animal feeds 
M, Hm 
Aflatoxin B1 and other 
aflatoxins 
Aspergillus flavus, 
Aspergillus parasiticus 
Peanuts, corn, cotton seed, 
cereals, figs, most tree nits, 
milk, sorghum, and 
walnuts. 
H,C,M,T 
Citrinin Penicillium citrinum Barley, corn, rice, walnuts. Nh, C, M 
Cyclopiazonic acid Asprgillus flavus, 
 P. cyclopium 
Peanuts, corn, cheese Nr, Cv 
Deoxynivalenon  Fusarium graminarum Wheat, corn Nr 
Cyclochlorotine P. islandicum  Rice H,C 
Fumonisins F. moniliforme Corn, sorghum H, Nr, C(?),R 
Luteoskyrin P. islandicum,  
P. ruguulosum 
Rice, sorghum H, C, M 
Monoliformin F. monoliforme Corn Nr, Cv 
Ochratoxin A Aspergillus ochraceus 
P. verrucosum 
Barley, beans, cereals, 
coffee, feeds, maize, oats, 
rice, rye, wheat 
Nh, T 
Patulin P. patulum, P. urticae, 
Aspergillus clavatus 
Apple, apple juice, beans, 
wheat 
Nr, C(?), M 
Penicillic acid P. puberulum, Aspergillus 
ochraceus 
Barley, corn Nr, C (?), M 
 Penitrem A P. paitans Feedstuffs, corn Nr 
Roquefortine P. roqueforti cheese Nr 
Rubratoxin B P. rubrum, P. 
purpurogenum 
Corn, soybeans H, T 
Sterigmatocystin Aspergillus versicolor, 
Aspergillus nidulans 
Corn, grains, cheese H, C, M 
T-2 Toxin F. sporotrichioides Corn, feeds, hay D, ATA, T 
12-13 F. nivale Corn, feeds, hay, peanuts, 
rice 
D, Nr 
Epoxitrichothecenes 
other than T-2 and 
DON Zearalenone 
F. grminearum Cereals, corn, feeds, rice G.M 
Cv = cardiovascular lesion; D = dermatoxin; G = genitotoxin and estrogenic effects; H = hepatotoxic; 
Hr = hemorrhagic; M = Mutagenic; Nr = neurotoxins; R = respiratory; T = teratogenic; C = 
carcinogenic; C(?) = Possible carcinogenic effect; ATA = Alimentary toxin aleukia; P. = Penicillium; F 
= fusarium. 
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Of the various mycotoxins, aflatoxins are most widespread and high priority is 
given to its regulation due to carcinogenic, immunosuppressive and teratogenic nature. 
Although several Aspergillus species produce aflatoxins, A. flavus is the most 
commonly occurring species and it is highly aggressive.  
 
2.2. Overview of aflatoxins and their derivatives 
Aflatoxins are a group of closely related secondary metabolites of the fungi A. flavus 
and A. parasiticus. A. flavus produces aflatoxin B1 (AFB1) and aflatoxin B2 whereas 
A. Parasiticus produces aflatoxin B1, B2, G1 and G2. Of these four, AFB1 is most 
potent toxin (Payne, 1998; Abramson, 1998). AFB1 is produced by A. flavus, A. 
parasiticus, A. nomius, A. bombycis, A. ochraceoroseus, A. pseudotamarii and 
Emericella venezuelans, on a wide range of tropical and subtropical agricultural 
commodities (http://www.anci.cornell.edu/plants/toxicagents/mycotoxin.html ). Of the 
various species, A. flavus is most widespread and common. It is a saprophyte during 
most of its life cycle and grows on a variety of substrates including decaying plant and 
animal debris. The major factors that influence soil populations are temperature and 
soil moisture. A. flavus can grow at temperatures from 12-48 ºC and at water potentials 
as low as –35 Mpa (Klich et al., 1994). The optimum temperature for growth is 25 to 
42 ºC. The fungi most commonly occur on groundnut (Arachis hypogaea), maize (Zea 
mays), several tree nuts (pistachio, cashew nuts, Brazil nuts, etc.), figs (Ficus carica), 
and on many other crops. Contamination mostly occurs on post-harvest products, 
stored at high temperatures and high humidity, but also known to occur in the fields 
before harvest on crops subjected to drought stress (Payne and Brown, 1998; Waliyar 
et al., 2003). 
 
Aflatoxins are basically difuranocoumarin compounds, which include aflatoxin B1, 
B2, B2a, G1, GM1, G2, G2a, M1, M2, GM2, P1, Q1, R0, RB1, RB2, AFL, AFLH, 
AFLM, and methoxy, ethoxy and aceto derivatives (Bilgramy and Choudhary, 1998). 
They are closely related compounds with small differences in chemical composition 
(structures of few aflatoxins given in Fig. 1). Several mycotoxins exert biological 
actions that impair the effectiveness of native defense mechanisms and immunity (Pier 
et al., 1979). AFB1 (C17H12O6) is the naturally occurring and most prevalent form and 
also the most potent of these toxins. It is a hepatotoxin, a hepatic carcinogen and 
mutagen. Toxin response depends on how the molecule is metabolized in the liver. It is 
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commonly associated with human liver cancer in association with Hepatitis B virus 
(HBV) infection (Kirk et al., 2005).  The chemical and physical properties of 
aflatoxins and its derivatives are given in Table 2. 
 
Table 2. Chemical and physical properties of aflatoxin and its derivatives 
(Bilgramy and Choudhary, 1998) 
 
Aflatoxin Molecular 
formula 
Molecular Weight Melting Point 
B1 C17H1206 312 268-269 
B2 C17H1406 314 286-289 
G1 C17H1207 328 244-246 
G2 C17H1407 330 237-240 
M1 C17H1207 328 299 
M2 C17H1407 330 293 
B2A C17H1407 330 240 
G2A C17H1408 346 190 
 
 27
Figure 1. Structure of aflatoxin B1 and its derivatives (Sabioni and Sepai, 1998) 
(f) Aflatoxin M2 
(g) Aflatoxin G2A (h) Aflatoxin B2A 
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2.3. Economic impact of aflatoxins 
The economic impact of aflatoxins derives directly from crop and livestock losses, 
human health as well as indirectly from the cost of regulatory programs designed to 
reduce risks to animal and human health. As per the FAO estimates, about 25% of the 
world’s food crops are affected by mycotoxins, of which the most dangerous is 
aflatoxins (Garcia and Park, 1998). Aflatoxin losses to livestock and poultry producers 
from aflatoxin-contaminated feeds include death and the more subtle effects of 
immune system suppression, reduced growth rates and losses in feed efficiency. Other 
adverse economic effects of aflatoxins include lowered market potential of food and 
fiber crops.  
 
2.4. Affects of aflatoxins on health 
The historic discovery of aflatoxins was due to the death of turkeys in the United 
Kingdom as a result of consuming contaminated groundnut meal imported from Brazil 
(Bhat et al., 1978). The harmful effects of consuming contaminated groundnut cake 
have been mainly observed in poultry and milch cattle (Bhat et al., 1978). The effect 
of poultry includes mortality, feed refusal, slowed growth, fertility and reproduction 
problems, and decreased resistance to diseases. Cattle fed with aflatoxin-contaminated 
feed result in secretion of metabolites of aflatoxin (AFM1) in the milk.  
 
Early signs of aflatoxicosis in livestock are reduction in feed intake and weight 
loss, often followed by rapid death. The susceptibility of the animals depends on the 
species (ducklings, rabbit, turkey, chicken, swine, cattle, and sheep in decreasing 
order), the form of aflatoxin and on the animals’ nutritional status. The liver is the 
primary target organ in most cases. 
 
2.4.1. Clinical pathology: The clinico-pathologic features of aflatoxins depend on 
hepatic injury. It is dose dependent. Doses adequate to produce death within 24 hours 
will result in detectable liver damage within 3 hours and several alterations in liver 
function within 6 hours. Marked elevation in the serum alanine transferase (SAT), 
ornithine carbamyl transferase, and isocitrate dehydrogenase (IDH) were reported. 
Reduction in the serum levels of albumin, albumin-globulin ratio, non-protein nitrogen 
(NPN), and urea were also reported (Edds, 1979). 
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A constant response to AFB1 is the proliferation of small bile ductules. This is 
usually accompanied by loss of hepatic glycogen, fatty infiltration, fibroblastic 
proliferation, and perivascular edema (Nelson, 1979). These degenerative changes lead 
to necrosis that is usually localized in one part of the lobule (centrolobular or 
midzonal). Edema of the gallbladder has frequently been noted in pigs (Nelson, 1979).  
 
Carcinogens at the cellular level cause degranulation of the endoplasmic membranes. 
Hepatic changes at the cellular level in aflatoxin-treated calves were: loss of ribosomes 
from the endoplasmic reticulum, loss of nuclear chromatin material and altered nuclear 
shapes (Lynch et al., 1971). For example in cattle, AFB1 is metabolized by hepatic 
microsomal mixed function oxidase. The hydroxylation of AFB1 to AFM1 during 
lactation is of particular concern. AFM1 is also found in the liver, kidney and urine of 
sheep (Masri et al., 1974)  
 
Aflatoxicosis in farm animals produces growth retardation, fatty liver and a 
decrease in the lipid content of extra hepatic tissues. The accumulation of fat in liver 
has been suggested to be due to a blockade to fat removal from the liver. The aflatoxin 
effect on lipid metabolism is also marked by reduction in such fat-soluble vitamins as 
vitamin A (Lynch, 1979).  
 
However, the major effect of aflatoxin is on the cell-mediated immune system. 
This failure has been demonstrated in poultry as fowl cholera and in swine as 
erysipelas. Aflatoxin consumption has also been reported to increase susceptibility of 
poultry to salmonellosis, candidosis and coccidiosis and of calves to fascioliasis (Pier 
et al., 1979). The diminished resistance and immunity are thus a problem of substantial 
economic importance. 
      
2.4.2. Ducks and poultry: Ducklings are the most susceptible class of livestock to 
aflatoxicosis and are preferentially used in bioassays for aflatoxins in feeds. Ducklings 
show a decreased utilization of dietary protein on diets containing even 70 µg kg-1 
AFB1. Whereas chickens show lowered levels of performance on diets containing 
>250 µg kg-1 AFB1, at higher levels (>500 µg kg-1), liver lesions become severe. 
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2.4.3. Swine: Relatively low concentration of aflatoxin B1 reduces average daily gain 
and feed efficiency in piglets fed on contaminated maize, but this affect was reversed 
by increasing the concentration of crude protein in the diet and by the addition of fat. It 
was shown that aflatoxin levels of 100 to 300 µg kg-1 in swine rations usually do not 
produce toxin effects from weaning to market, but, levels greater than 400 µg kg-1 may 
produce aflatoxicosis (Edds, 1979). Residues of AFB1 and AFM1 may be present in 
liver, kidney and muscle tissues in swine fed on diets containing only 100 µg kg-1 
aflatoxin B1 and these residues may be hazardous for human consumption (Edds, 
1979).  
 
2.4.4. Ruminants: Rumen fermentation does not appear to detoxify aflatoxins, but 
aflatoxins may inhibit rumen microorganisms. Only 0.7% to 1.4% of an oral dose of 
AFB1 was excreted in milk from lactating goats, 25% of the aflatoxin in this milk was 
M1. About 50% of the oral dose was detected in feces (Helferich et al., 1986). 
 
2.5. Biochemical pathway involved in metabolism of aflatoxin in human 
Aflatoxins are activated by several cytochrome P-450s, including CYP2A3, CYP2A6 
and CYP3A4 (Wojnowski et al., 2004). AFB1 and G1 (Fig. 1a, and c) have an olefinic 
double bond at the 8,9-position, and they are more mutagenic and carcinogenic than 
aflatoxin B2 and G2 (Fig. 1b,d), which are saturated and have an ethylenic bond at this 
position. This implies that the olefinic 8,9-bond is the site of activation. 
 
AFB1 (Fig. 1a) is metabolized to AFB1 8,9-eopoxide, which can bind to protein 
and DNA, predominantly at the N7 position of guanine. AFB1 reacts with hepatic 
macromolecules and with serum albumin in a dose dependent manner. The important 
step in the process of carcinogenesis is the formation of AFB1-epoxide. AFB1 is 
activated by cytochrome P450 to AFB1 8,9-exo epoxide (Fig. 2B) and AFB1 8,9-endo 
epoxide. But it is the exo epoxide which binds to form the predominant AFB1- N7 
guanine adducts (Fig. 2E). The epoxide ring is positioned above the plane and in trans 
to the 5a and 9a protons in the endo epoxide, hindering the reaction. But in the exo 
epoxide, the epoxide ring is positioned below the plane and in cis to the 5a and 9a 
protons assisting the reaction (Wild and Turner, 2002).  
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AFB1 itself is a relatively innocuous molecule but cytochrome P450 enzyme and 
some other oxygenases (to a lesser extent) oxidize it to the 8,9 epoxide, which has a 
central role in all succeeding reactions (Guengerich et al., 2002). 8,9-exo epoxide 
hydrolyzes rapidly to dihydrodiol (Fig. 2C) that in turn undergoes slow, base-catalyzed 
ring opening to a dialdehyde phenolate ion. AFB1 dialdehyde does not bind to DNA 
but forms Schiffs base with primary amine groups, e.g. lysine, to form protein adducts 
such as aflatoxin albumin (Fig. 2F).  
 
The formation of AFB1-glutathione adduct is an important detoxification pathway. 
This process is catalyzed by species-specific glutathione-S-transferase (GST). It 
appears that animals that are very susceptible to AFB1 lack an efficient GST. One 
percent to two percent of the administered dose is excreted into urine as the 
glutathione (Raj and Lotlikar, 1984).  
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Figure 2: Major reactions in AFB1 metabolism (Figure source, Guengerich et al., 2002) 
(A) (B) (C) (D) 
(E) 
(F) 
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2.6. Toxic affects of aflatoxins in humans and animals                                                                             
Aflatoxicosis is the poisoning that results from ingesting aflatoxins. Two forms of 
aflatoxicosis have been identified 
? Acute severe intoxication, which results in direct liver damage and subsequent 
illness or death. 
? Chronic sub symptomatic exposure (leads to cancer, immuno suppression, etc.). 
 
2.6.1. Acute illness and death 
High levels of aflatoxin exposure produces an acute necrosis, cirrhosis and carcinoma 
of liver exhibited by hemorrhage, acute liver damage and edema, alteration in 
digestion and absorption and metabolism of nutrients (Williams et al., 2004). No 
animal species is immune to the acute toxic effects of aflatoxins including humans. 
However, humans have an extraordinarily high tolerance for aflatoxin exposure and 
rarely succumb to acute aflatoxicosis. 
 
Animals were found to differ in the median lethal dose for AFB1. Susceptible 
species such as rabbits and ducks have a low (0.3 mg kg-1) median lethal dose, whereas 
chickens (18 mg kg-1) and rats have greater tolerance. Adult human usually have a 
high tolerance of aflatoxin and in the reported acute poisoning, it is usually the 
children who are most vulnerable to aflatoxin-related deaths. Economic pressures have 
created a double standard for allowable contamination of commodities destined for 
human and animal consumption. Human foods are allowed 4-30 ppb aflatoxin, 
depending on the country involved (Henry et al., 1999). The maximum allowable 
limits of mycotoxins in India and in US were given in Table 3 and Table 4 
respectively. 
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Table 3. Maximum allowable limit of mycotoxins in foodstuffs, dairy products 
and animal feedstuffs in India 2002-2003 survey (FAO, 2004) 
 
Commodity Mycotoxins Limits (µg kg-1) 
Food: all food products AFB1, B2, G1, G2 and M1 30 
Feed: Peanut meal (export) AFB1 120 
 
 
 
 
 
Table 4. Maximum allowable limit of aflatoxin in United States (FAO, 2004) 
 
Aflatoxin Concentration 
PPB (Parts per billion) 
Affects on animal Health 
20 Highest level allowed for humans 
50 Highest level allowed for animals 
100 Slowed growth of young ones 
200-400 Slowed growth of adults 
>400 Liver damage and Cancer 
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2.6.2. Chronic affects of aflatoxin exposure  
Chronic sub-clinical exposure does not lead to as dramatic symptoms as acute 
aflatoxicosis. Children however are particularly affected by aflatoxin exposure, which 
leads to stunted growth and delayed development. Chronic aflatoxin exposure has 
major effects on nutritional status in animals, but, as with immunotoxins, thresholds 
for these effects were not defined for any species (Roebuck and Maxuitenko, 1994). 
Chronic exposure also leads to a high risk of developing liver cancer, as the metabolite 
AFB1 can intercalate into DNA and alkalate the bases through its epoxide moiety 
(Roebuck and Maxuitenko, 1994).  
 
2.6.2.1. Cancer: Hepatocellular carcinoma (HCC) is the sixth most common cancer, 
accounting for about 5% of all human cancers and the second cause of cancer death in 
the world (Behnoush et al., 2011). For humans, aflatoxin is predominantly perceived 
as an agent promoting liver cancers. The International Agency for Research on Cancer 
(IARC) classified AFB1 as a Class 1 carcinogen. A strong synergy has been shown 
between aflatoxin and Hepatitis B virus (HBV) and C virus (HCV). In HBV infected 
persons, aflatoxin is 30 times more potent than in persons without the virus. The 
suggested mechanism for the synergy is that aflatoxin suppresses DNA repair 
mechanism that helps limit the development of cancer from HBV (Williams et al., 
2004). A factor in this greater potency of aflatoxin in HBV positive people is that 
HBV reduces the person’s ability to detoxify aflatoxin. In some areas where aflatoxin 
contamination and HBV occur together, hepatomas are the predominant cancer and 
they may be a major cause of death (Henry et al., 2002).  
 
2.6.2.2. Aflatoxin induced mutation: 
Epidemiological studies in high aflatoxin contaminated areas indicate that dietary 
AFB1 contributes to the development of HCC and the two main risk factors, HBV and 
AFB1, have a synergistic effect in liver carcinogenesis (Jiang et al., 2005). The 
molecular hallmark of AFB1 intoxication in relation to HCC is a specific mutation at 
codon 249 of the TP53 gene. This mutation is a single-base substitution at the third 
base of codon 249 (AGG to AGT), which replaces an arginine “R” by a serine “S”. 
This mutation has been reported in about 75% of HCC cases in high incidence areas 
(China or East Africa). Such a mutation is not detected in HCC cases from non-
aflatoxin contaminated areas (Montesano et al., 1997).  
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2.6.2.3. Immunologic suppression: In animal experiments, AFB1 has been shown to 
induce thymic aplasia, reduce T-lymphocyte function and number, suppress 
phagocytic activity and reduce complement activity. Many studies conducted in 
poultry, pigs, and rats showed that exposure to aflatoxin results in suppression of the 
cell-mediated immune response. (Pier, 1986; Reddy et al., 1987; Richard et al., 1978). 
 
Macrophages play a major role in host defense against infection. They present 
antigen to lymphocytes during the development of specific immunity. Macrophages 
also increase their phagocytic activity and release various active products, such as 
cytokines and reactive intermediates, to carry out nonspecific immune responses. 
Several reports suggest that aflatoxin impairs the function of macrophages in animal 
species (Neldon-Ortiz, 1991).  
 
2.6.2.4. Human studies: Jiang et al. (2005) studied the aflatoxin levels and cellular 
immune status in Ghanaians. They examined the cellular immune status in relation to 
levels of AFB1 –albumin adducts in plasma. The percentage of leukocyte 
immunophenotypes in peripheral blood, CD4+ T cell proliferative response, CD4+ Th 
and CD8+ T cell cytokine profiles and monocyte phagocytic activity were measured 
using flow-cytometry.  They showed that participants with high AFB1 level had 
significantly lower percentages of CD3+ and CD19+ cells.  Also, the percentage of 
CD8+ T cells that contained perforin or both perforin and granzyme A were 
significantly lower in participants with high AFB1 levels when compared with low 
AFB1 level (Jiang et al., 2005).  
 
2.7.Overview on methods for the detection of aflatoxins 
Ensuring the safety and wholesomeness of foods would be impractical without reliable 
methods of laboratory analysis to determine whether products are up to specified 
standard (Wood and Trucksess, 1998). Many methods are available for the estimation 
of aflatoxins. However, it is important to choose the method that gives the most 
reliable results for the commodity being analyzed. The traditional method for analysis 
includes Thin Layer Chromatography (TLC) and High Performance Liquid 
Chromatography (HPLC). The basic steps in each method include extraction, liquid 
partition, purification, separation and quantification. Recently, several simple but 
sensitive ELISA method have been developed, evaluated and approved for qualitative 
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screening and quantification of aflatoxins (Trucksess and Wood, 1994; Anitha et al., 
2011)).  
 
2.7.1. Analytical methods 
2.7.1.1 Thin layer chromatography (TLC), also known as flat bed chromatography 
or planner chromatography, is one of the widely used methods in aflatoxin analysis. 
Since 1990, it has been considered the official method of the Association of Official 
Analytical Chemist (AOAC) and the method of choice to identify and estimate 
aflatoxins as low as 1 ng g-1. TLC needs high sample purification. The major 
disadvantage is that the procedure is inherently variable, so the coefficient of variation 
is large and the precision poor (Wilson et al., 1998). 
 
2.7.1.2. High Performance Liquid Chromatography (HPLC) gives an accurate 
quantification of the aflatoxin from the various samples, including blood. But, the 
success of HPLC separation for mycotoxin analysis depends on factors such as 
extraction, cleanup, concentration, separation, detection techniques and HPLC 
conditions suitable for the specific compounds and matrices of concern (Wilson et al., 
1998), which makes this technique difficult. Liquid chromatography requires analytic 
application, stationary phase and mobile phase. Liquid chromatography methods for 
the detection of aflatoxins in foods include normal phase LC (NPCL), reverse phase 
LC (RPLC), with pre or before column derivatization (BCD), RPLC followed by post 
column derivatization (PCD), and RPLC with electrochemical detection (Wilson et al., 
1998). 
 
Usually, in analytical techniques like TLC and HPLC, the extracted sample needs 
clean up before analysis, to remove co-extracted materials that often interfere with the 
determination of the target. Both the TLC and HPLC are laborious and time 
consuming.  
 
2.7.2. Immunological methods 
Immunological methods using polyclonal or monoclonal antibodies have become the 
cornerstone of rapid testing of foods and feeds for aflatoxins and other mycotoxins 
(Wilson et al., 1998). Immunological recognition is based on the special complement 
of specific groups of the antigen with those of the antibody. Since mycotoxin 
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molecules (including AFB1) cannot elicit immune response, the molecules are 
conjugated to carrier proteins for immunization purpose (Chu, 1994). For instance, 
polyclonal antibodies are produced against AFB1 by immunizing animals with a 
AFB1-bovine serum albumin (BSA) conjugate (Waliyar et al., 2005). For aflatoxin 
detection in blood, polyclonal antibodies have to be raised against the aflatoxin-lysine 
derivative, which is conjugated to carrier protein like BSA. Similar immunization 
procedure is followed even for the production of monoclonal antibodies. The 
monoclonal antibodies are generally raised by the fusion of immunized mice spleen 
cells with a myeloma cell line (Chu, 1994). Various serological methods such as 
ELISA, Radio Immuno Assay (RIA), immunoaffinity column assay (ICA) and lateral 
flow assays have been developed for the estimation of aflatoxins in various crops, 
commodities, milk and even in blood (Chu, 1990).   
 
2.7.2.1. ELISA: It is a highly sensitive, simple and cost-effective technique. It is based 
on an antigen antibody reaction. It gives accurate quantification of aflatoxin in various 
commodities, including estimation of aflatoxin exposure in blood by detecting AFB1-
lys. Sample clean-up is not necessary after extraction. The results are reproducible and 
comparable with HPLC. Because of all these advantages, many researchers are now 
concentrating on this technique.  
 
Two types of ELISA have been used in the analysis of aflatoxins: (i) Indirect ELISA 
(Fig 4); and (ii) Direct ELISA. Both forms are heterogenous competitive assays, which 
involve the separation of free (untreated) toxin in liquid phase from the bound toxin in 
solid-phase. 
 
2.7.2.2. Direct Competitive ELISA: In the typical, direct ELISA, the binding of 
aflatoxin-enzyme conjugate by the immobilized antibodies is inhibited by the presence 
of aflatoxin in the test sample. The bound enzyme catalyzes the transformation of the 
substrate to a coloured complex. The colour intensity formed is inversely related to 
aflatoxin concentration. Alkaline phosphatase and horse radish peroxidase catalyze the 
oxidation of the substrates, para- nitrophenyl phosphate and tetramethylbezidine, 
respectively, to form a yellow and blue coloured complexes, respectively (Wilson et 
al., 1998). ELISA plates, beads, membranes (cup, card, probe test) have been used as 
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solid support for ELISA. This is technically more demanding and requires conjugation 
of enzyme label directly to the anti-aflatoxin antibodies. 
 
2.7.2.3. Indirect competitive ELISA: In the indirect ELISA the binding of primary 
antibody to the immobilized antigen is inhibited by the presence of aflatoxin in the test 
sample. The secondary antibody that is conjugated to the enzyme can find the primary 
antibody and the addition of substrate is catalyzed by the enzyme conjugate. This 
produces colored product. The intensity of the colour developed is inversely related to 
aflatoxin concentration (Fig. 4). 
 
2.7.2.4. Radio immno assay (RIA): The principle is similar to that of ELISA. But, 
radiolabeled aflatoxin is used in RIA. In competitive RIA, the unlabelled aflatoxin 
standard or the aflatoxins in the test solution and the labeled aflatoxin in the assay 
system are competing for the limited number of binding sites on the antibodies (Chu, 
1990). The amount of aflatoxins in a sample is inversely related to the amount of 
radiolabeled aflatoxin in the solution. Only a small amount of antibody is required for 
RIA. However, the radioisotopes used in the assays present disposal problems. 
Therefore, the use of non-isotopic labels such as enzymes has gradually replaced the 
use of RIA.  
 
2.7.2.5. Immuno affinity column assay: Affinity columns are prepared by adsorption 
of the antibodies onto a gel material contained in a small plastic cartridge. Aflatoxins 
are captured from test solutions by the immunospecific antibodies (Trucksess et al., 
1991). After non-binding impurities have been washed from the cartridge, aflatoxins 
are desorbed with methanol, then estimated by solution fluorometry or transferred to 
the liquid chromatographic reversed-phase column for further separation and 
fluorescence determination (Chu, 1992). The use of affinity columns to capture and 
concentrate aflatoxins has several advantages: increased selectivity, the ability to trap 
the aflatoxins in large volumes of test samples (biological fluids), and integration with 
other analytical techniques. However, large amounts of antibodies are needed to 
prepare the immunosorbent columns and the cost is greater than RIA and ELISA. 
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2.8. Aflatoxin detection in blood and urine 
Epidemiological studies in the areas of high incidence of hepatoma throughout Africa 
and Southeast Asia have suggested that the exposure to aflatoxins may play a role in 
primary liver cancer (Rose et al., 1992). It has not been clarified whether aflatoxin 
alone or an interaction with HBV infection cause the hepatomas (Rose et al., 1992). 
This has necessitated the need for methods to determine the human exposure to 
aflatoxins, to assess the risk of liver cancer and other aflatoxin-related illnesses and, to 
demonstrate the relationship between exposure to aflatoxins and the etiology of 
disease. Now, various methods have been developed to measure aflatoxin metabolites 
in milk, sera and urine (Wilson et al., 1998). 
 
Accurate and sensitive biological markers of carcinogen (aflatoxin) exposure are 
now used to estimate cancer risk. Biomarkers can be metabolites, DNA adducts or 
protein adducts. Knowledge of the metabolic fate of AFB1 has led to the use of several 
biomarkers in blood, urine, feces and tissues that can be used to monitor AFB1 
exposure. AFB1 is among the few compounds for which the relationship between 
biomarkers and exposure has been extensively studied (Turner et al., 1998).  
 
There are two techniques that have been used most often to detect levels of 
aflatoxin in humans. The first method is measuring the DNA adducts, AFB1-guanine, 
in the urine of subjects. Aflatoxin once ingested is metabolized by the cytochrome 
P450 system, primarily in the liver. The resulting reactive AFB1-8,9-epoxide binds to 
DNA (Essigman et al., 1977; Martin and Garner, 1977), forming AFB1-guanine 
adduct. Presence of these breakdown products indicates exposure to aflatoxin in the 
past 24 hours. However, this technique has a significant flaw in that it only produces a 
positive result in approximately one third of positive test subjects. Additionally, due to 
the half-life of this metabolite, the level of AFB1-guanine measured can vary 
significantly from day to day, based on diet. Thus, is not useful for assessing long term 
exposure. The persistence of AFB1-formamidopyrimidine DNA adduct may be a 
useful biomarker of AFB1 exposure but is limited by availability of tissue. 
 
Another technique is the measurement of the AFB1-albumin adducts level in the 
blood serum. AFB1-8,9-epoxide formation also leads to AFB1-protein binding via 
AFB1-8,9-dihydrodiol (Sabbioni et al., 1987). This binding occurs specifically to the 
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amino acid, lysine, of albumin. Because human albumin has a half-life of 
approximately 20 days, AFB1-albumin adduct detection provides a useful biomarker 
of cumulative AFB1 exposure. Also, it is less invasive to collect blood samples for 
analysis than to surgically remove tissue samples from individual. This approach is 
significantly more accurate, as positive results are generated in 90% of positive test 
subjects (Turner et al., 1998). This test is also useful for measuring long-term 
exposure, as it remains positive for two to three months. 
 
Previously, AFB1-lysine adduct was prepared by conjugating 8,9-dihydro-8,9-
dibromo-AFB1 (AFB1-dibromo) with N- acetyl lysine for in vitro reaction instead of 
AFB1-epoxide (Sabbioni and Sepai, 1998). Preparation of later is simpler and more 
convenient and is widely used (Fig. 3).  
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Figure 3. AFB1-lysine conjugate (figure provided by Dr. Sabbioni through mail) 
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Figure 4. Indirect competitive ELISA for AFB1 positive and negative samples 
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2.9. Management of aflatoxins in plants and human 
Human and animal exposure to aflatoxins can be reduced by mitigating aflatoxin 
contamination in food and feed (Turner et al., 2005). However, aflatoxin 
contamination is a complex problem and is influenced by diverse factors such as 
cropping practices, climate and socioeconomic background of the people (Waliyar et 
al., 2005b). Aflatoxin contamination of food is severe after long-term crop storage 
because of excessive heat, humidity; insect and rodent damage resulting in 
proliferation and spread of fungal spores. The main crops affected include maize and 
groundnuts, which, together, are the staple diet in many parts of sub-Saharan Africa. 
Groundnut is the most important oilseed crop in developing countries. Groundnut seed 
is the valuable source of protein for human and animal nutrition. India and China alone 
contribute to nearly 2/3rd of the world production. 
 
The traditional approach to preventing exposure to aflatoxin has been to ensure 
that foods consumed have the lowest practical aflatoxin concentrations. In developed 
countries, this has been achieved for humans largely by regulations that have required 
low concentrations of the toxin in traded foods. However, this approach has certain 
limitations and clearly has failed as a control measure for developing countries. In 
developed countries, where regulations allow higher aflatoxin concentrations in 
animals, agricultural industries have developed alternative methods like 
chemoprotection and enterosorption to limit biologically effective exposure without 
the high cost of preventing contamination (Galvano et al., 2001). Chemoprotection is 
based on manipulating the biochemical processing of aflatoxin to ensure detoxification 
rather than preventing biological exposure. Enterosorption is based on the approach of 
adding a binding agent to food to prevent the absorption of the toxin while the food is 
in the digestive tract; the combined toxin-sorbent is then excreted in the feces. This 
approach has been used extensively and with great success in the animal feeding 
industry (Williams et al., 2004). 
 
It is well understood that much of the contamination of commodities with aflatoxin 
occurs during storage. To preserve aflatoxin production during storage, it is necessary 
to prevent growth of fungus through adequate drying (<10% moisture), elimination of 
insect activity that can increase moisture content through condensation of moisture 
resulting from respiration, low temperature, and inert atmospheres. Conditions needed 
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to prevent aflatoxin contamination are known, but is not always easy to produce them 
in storage systems in developing countries. Most people in rural areas grow and store 
their own food; in consequence, most food is stored in small, traditional granaries and 
there is little investment in the management of ideal storage conditions. Studies of 
grain quality in such storage structures show a steady increase in the aflatoxin content 
over time, which reflect the failure to maintain appropriate conditions (Turner et al., 
2005).  
 
Several approaches can prevent aflatoxin exposure in developing countries. 
Because much food contamination occurs during post harvest storage, methods to 
remove nuts or kernels damaged by fungus before storage and to restrict humidity 
during storage could reduce fungal growth and toxin production. The possible options 
for pre and post harvest prevention of aflatoxin contamination and the ICRISAT’s 
management strategy of pre- and post-harvest contamination has given in Table 5 and 
Figure 5, respectively (Waliyar et al., 2005b).  
 
Turner et al. (2005) demonstrated a method for reduction in exposure to 
carcinogenic aflatoxins by post harvest intervention measures in West Africa. They 
selected a few villages, which have similar climate as well as same practice of 
groundnut cultivation, harvesting and storage. In ‘control villages’ farmers were left to 
follow their usual post harvest practices. In ‘test villages’, they were given a package 
to follow. This included hand sorting- damaged kernels which were removed and 
discarded before storage. Modification to usual drying procedures (drying on mats - 
spread on the ground for sun drying) make ground nut susceptible to humidity and 
difficult to gather in the event of unexpected rain. Therefore, locally produced natural-
fiber mats were used for the sun drying process. Incomplete sun drying leaves residual 
humidity in the groundnuts during storage. Farmers were shown how to judge the 
completeness of sun drying by shaking the kernels to listen for the free movement of 
the dried nuts. Use of plastic or other synthetic bags for storage, rather than natural 
fiber bags promotes humidity. So, they provided the natural fiber jute bags. Storing the 
bags of groundnut bags on the floor leads to the risk of attracting humidity. Hence, to 
avoid that, wooded pallets were provided, on which the bags were kept. Insecticides 
were provided for sprinkling in small quantities on the floor of the storage facility 
under the wooden pallets at the start of the storage and intermediately afterwards. To 
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monitor the effectiveness of the intervention study, blood sample were taken and 
aflatoxin–albumin adduct level were measured by ELISA.  
 
Table 5. A few options to reduce pre- and post-harvest contamination in crops 
(Waliyar et al., 2005b) 
Method Purpose 
I. Primary prevention To minimize fungal infestation and 
aflatoxin contamination 
? Cultivation of A. flavus resistant 
varieties 
? Potential for control of fungal invasion 
and toxin production during crop 
growth. 
? Control of field infection by following 
appropriate phytosanitary measures to 
reduce the fungal inoculum 
? Limit fungal inoculum in the field 
? Seed treatment and application of 
fungicides 
? Limit fungal invasion during crop 
growth 
? Appropriate scheduling for planting, 
harvest and post harvest 
? Avoid drought stress and other abiotic 
stresses 
? Application of soil amendments 
(gypsum, farmyard manure etc 
? Enhancing soil nutrient (especially 
calcium) and water holding capacity, 
promoting the growth of antagonistic 
native soil-microflora  
? Lowering moisture content of seeds 
after harvesting and during storage 
? Limit fungal invasion and growth 
during storage 
? Preservatives to prevent insect 
infestation and fungal contamination 
during storage 
? Limit fungal invasion during storage 
II. Secondary prevention Elimination or limiting the fungal 
contamination 
? Sorting of contaminated pods and 
kernels 
? Reducing aflatoxin contamination in 
final product 
? Re-drying the groundnut pods and 
kernels 
? Limit further mold invasion during 
storage 
? Appropriate storage conditions to 
avoid favorable conditions for mold 
growth 
? Limit further mold invasion during 
storage 
? Detoxification of contaminated 
product 
? Chemical inactivation of aflatoxins 
through use of detoxification clay, 
ammonification, electronic sorting of 
kernels. 
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Since Aspergillus and aflatoxin contamination were already present in the field but 
then increase during storage, the post harvest adduct concentration was same in both 
‘test’ and ‘control’ villages.  But, during storage, the concentration increased in 
‘control’ villages compared to the ‘test’ villages. In ‘control’ villages the mean adduct 
level increased during 5 months of storage from 5.5 pg mg-1 (immediately post 
harvest) to 18.7 pg mg-1. In contrast, the mean adduct concentration in the 
‘test’villages after 5 month of storage was much the same as that immediately post-
harvest (7.2 pg mg-1 to 7.0-9.0 pg mg-1). At the end of the study period, mean 
concentration in the ‘test’ villages was less than 50% of the ‘control’ villages. The 
numbers of individuals exposed to toxin were also studied. After the 5-month storage 
period, only five (2%) people had non detectable concentration in ‘control’ villages 
compared with 47 (20%) of those in the ‘test’ villages.  
 
The community-based intervention has shown to have a striking reduction in 
aflatoxin exposure by use of simple, low technology post harvest practices in a rural 
subsistence-farming community in Africa. Exposure was more than halved 5 months 
after harvest in individuals from the intervention villages. Moreover, only 2% of 
individuals in the control villages had undetectable concentrations of aflatoxin-
albumin adducts compared with about 20% in the intervention villages (Turner et al., 
2005). Such studies are necessary in developing countries in Asia to assess the risk of 
aflatoxin exposure and to implement suitable intervention strategies.  
 
Diekman and Green, (1992) have given the following suggestions to prevent 
mycotoxin contamination of feed stuffs:  
• Controlling the environmental factor that influence the growth of the fungus 
during storage i.e., moisture content of grain should be <14% 
• Relative humidity should be <70%; Temperature should be –2.2 centigrade 
• Oxygen availability should be <0.5% and also use of mold inhibitors and anti 
caking additive can reduce the fungus growth 
• The technique like floating separation can remove the fusarium–infected 
kernels that are lighter than sound kernel  
• Addition of 0.5% hydrated sodium calcium aluminosilicate in formulated feed 
can reduce the fungal infection 
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Figure 5.  Schematic representation of integrated management strategy for pre 
and post-harvest management of aflatoxins in groundnut (Waliyar et al., 2005b) 
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ICRISAT’s integrated approach for aflatoxin management for enhancing trade and 
human health is given in Fig 6. Anitha et al. (2007) initiated a ‘Top-Down Strategy 
(TDS)’ to prevent human exposure to aflatoxins (Fig.7). It involves identification of 
the most vulnerable groups who are at the risk of frequent exposure to aflatoxins. This 
is done by estimating the concentration of AFB1-lysine (a metabolite of aflatoxin in 
humans) in albumin fraction of blood, which has been shown to correlate with dietary 
aflatoxin intake over the previous 2-3 months (Turner et al., 2005). Subsequently, 
sources of dietary contamination would be identified by analyzing the agriculture and 
food production practices in the region to formulate a risk prevention strategy.  
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Figure 6: ICRISAT’s integrated approach for aflatoxin management for 
enhancing trade and human health. (Prepared by Dr.Lava Kumar in 2007) 
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Figure 7. Schematic representation of Top-down strategy (TDS) and Bottom-up 
strategy (BUS) for preventing human exposure to aflatoxins (Anitha et al., 2007) 
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3. MATERIALS AND 
METHODS 
 
 
 
 
 
 
 
 
 
 53
3.1. Production and characterization of polyclonal antibody 
 
3.1.1. Equipment, reagents and antibodies 
• Aflatoxin B1 (Sigma) 
• Bovine serum albumin (BSA) (Sigma) 
• Meta chloroperbenzoic acid (MCPBA) (ICN, Biochemicals, Ohio) 
• Dichloromethane (DCM) (ICN, Biochemicals, Ohio) 
• TLC plate- precoated, size (20 x 20cm), particle size 2-25 m Fisher Scientific’s 
• Anti-rabbit antibody conjugated with alkaline phosphatase (AR-ALP) (Sigma) 
• General chemicals for buffer preparations were obtained from Sigma, BDH and 
Qualigens.  
• Preparation of buffers for ELISA are given in the Appendix 
 
3.1.2. Preparation of AFB1- BSA adduct (Immunogen) (Sujatha et al., 2001) 
1. In 500 µl of DCM, 11.36 mg of MCPBA was added and this was saturated with 
0.1 M phosphate buffer. In another 500 µl of DCM 1550 µg of AFB1 was 
dissolved and mixed with MCPBA solution prepared in DCM. This was kept for 
gentle shaking at 5 ºC for 6 h for the formation of epoxide.  
2. Ten mg of BSA was dissolved in 500 µl of 0.1 M phosphate buffer and this was 
added to AFB1 epoxide and incubated overnight at 5 ºC with gentle shaking.  
3. The reaction mixture was centrifuged at 2,500 rpm for 5 min. The aqueous 
fraction was separated from the DCM fraction and washed thrice with DCM to 
remove traces of unreacted AFB1.  
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3.1.3. Estimation of AFB1-BSA adduct concentration 
The AFB1-BSA adduct concentration was estimated using spectrophotometer 
(Beckman DU530). Phosphate buffer was used as a blank control. The OD at 595 nm was 
measured. Phosphate buffer was used as a blank. (Bradford, 1976) 
Blank: To 1.8 ml of Bradford reagent 200 µl of PBS pH 7.4 was added. This was used 
for blank during spectrophotometric measurements. 
Sample: Five µl of albumin was diluted to 200 µl in PBS and to this 1.8 ml of Bradford 
reagent was added and mixed well and readings were taken at 595 nm in a 
spectrophotometer. 
 
3.1.4. Immunization of rabbit 
AFB1-BSA was used as an immunogen to produce antiserum. For immunization, 250 
µg AFB1-BSA in 250 µl of 0.1 M phosphate buffer, pH 7.2, was emulsified with an equal 
volume of Freund’s complete adjuvant and used for immunization via intramuscular 
injections at multiple sites into a New Zealand White inbred rabbit. Four subsequent 
injections were given at weekly intervals using AFB1-BSA emulsified in equal volumes 
of Freund’s incomplete adjuvant. The rabbit was bled for polyclonal antiserum a week 
after last injection for four weeks at weekly intervals. To improve the antibody titer, a 
week after the 4th bleed, the rabbit was given a booster immunization with AFB1-BSA 
emulsified in incomplete Freund’s adjuvant. After two weeks of rest, the animal was 
bleed for polyclonal antiserum at weekly intervals for eight weeks.  
 
The titer of each bleed of antiserum was determined by IC-ELISA performed in 96-
well microtiter plates (Maxi-sorp, Nunc) as described below. 
 
3.1.5. Monitoring antibody titers 
An indirect ELISA procedure similar to that reported for aflatoxin-albumin (Wild and 
chappot 1991) was used. Microtiter plates were coated with 10 ng mL-1 of aflatoxin-
ovalbumin in carbonate buffer pH 9.6 and incubated at 37˚C for 2 hrs. Antiserum was 
diluted in PBS containing 0.05% Tween 20. Antiserum dilutions (from 10,000 to 1: 
75000) in 50 µl were added  to 100 µl of AFB1-lysine ranging from 100 ng to 100 pg. 
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goat antirabbit immunoglobulins conjugated to alkaline phosphatase were used at  a 
1:1000 dilution to detect antibodies attached to AFB1-lysine. p-nitrophenyl phosphate 
was used as a substrate at 1mg ml-1 and allowed to develop for 1 hr at room temperature. 
Absorbance was recorded at 405nm with an ELISA plate reader. 
 
3.1.6. Characterization of antibody 
3.1.7.1. DAC-ELISA to check cross-reaction of antisera 
DAC-ELISA was performed to assess the antibody cross reaction. Plate was coated with 
100 and 25 ng of AFB1-BSA, BSA and ovalbumin and it was incubated overnight at 4˚C. 
Plates were washed and AFB1 epoxide-lys and AFB1 antiserum at 1:2000 and 1:60,000 
dilution, respectively, were added. ELISA plate was incubated at 37 ˚C for one hour. 
After washing, AR-ALP was added at 1:2,000 dilution and incubated for 1 h. Finally 
pNPP substrate was added at 1 mg ml-1 concentration; and the colour development was 
read at 405 nm. 
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3.2. Standardization of ELISA method to detect AFB1-lysine 
and Validation of ELISA method developed 
 
 
3.2.1. Preparation of standards and coating antigen 
AFB1-Lysine adduct prepared invitro was used as a standard and AFB1-ovalbumin 
adduct prepared invitro was used as coating antigen. The preparation of coating antigen 
and AFB1-Lysine standard is given bellow: 
 
3.2.2. Preparation of AFB1-lysine adduct 
AFB1-lysine (Fig. 8C) adduct was prepared in subdued light. Protocol given in Sujatha et 
al. (2001) with some modifications was used for the preparation of adduct. First, AFB1 
molecule was converted into epoxide (AFB1-8,9-epoxide; Fig. 8B) by oxidation with 
metachloroperbenzoic acid (MCPBA) (ICN, Biochemicals, Ohio) and it was used for 
conjugation with N-α-acetyl lysine (Sigma) to prepare AFB1-lys adduct as stated below.  
1. Six mg of MCPBA was dissolved in 2.5 ml of dichloromethane (DCM) and the 
solution was saturated with 0.1 M phosphate buffer. To this 1 mg of AFB1 was 
added and incubated with gentle shaking at 5 oC overnight for the formation of 
AFB1-8,9 epoxide.  
2. Ten mg of N-α- acetyl lysine was dissolved in 2.5 ml of 0.1 M phosphate buffer 
and this was added to the AFB1-8,9 epoxide and incubated overnight at 5 ºC with 
gentle shaking to allow the formation of AFB1-lys adduct .  
3. This mixture was centrifuged at 2,600 rpm for 5 min (Labofuge 400e, Heraeus 
instruments) to separate aqueous fraction (which contains AFB1-lys) from the 
DCM fraction. 
4. The aqueous fraction was washed thrice with DCM to remove residual AFB1.  
5. Aqueous and DCM fractions were analyzed by TLC to verify adduct synthesis. 
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Figure 8. Structure of AFB1-8,9-epoxide and AFB1-lys (source Guengerich et al., 2002) 
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3.2.3. Preparation of AFB1- ovalbumin adduct (Sujatha et al., 2001) 
4. In 500 µl of DCM, 11.36 mg of MCPBA was added and this was saturated with 
0.1 M phosphate buffer. In another 500 µl of DCM 1550 µg of AFB1 was 
dissolved and mixed with MCPBA solution prepared in DCM, and this was kept 
for gentle shaking at 5 ºC for 6 h for the formation of epoxide.  
5. Ten mg of ovalbumin was dissolved in 500 µl of 0.1 M phosphate buffer and this 
was added to AFB1 epoxide and incubated overnight at 5 ºC with gentle shaking.  
6. The reaction mixture was centrifuged at 2,500 rpm for 5 min. The aqueous 
fraction was separated from the DCM fraction and washed thrice with DCM to 
remove traces of unreacted AFB1.  
 
3.2.4. TLC to estimate the adduct formation  
Formation of AFB1-lys and AFB1-ovalbumin adducts were verified by TLC. For this 
each silica gel precoated TLC glass plate (20×20 cm) was activated for one hour at 110 
ºC before use. The aqueous fraction, DCM fraction, N-α-acetyl lysine, ovalbumin and 
AFB1 standards were spotted on TLC. The plate was developed in a chloroform : acetone 
(9:1) solvent. The developed plate was air-dried and visualized under long-wave 
ultraviolet (UV) light.  
 
3.2.5. Estimation of AFB1-lys and AFB1-ova adduct concentration 
The AFB1-lys adduct concentration was estimated using spectrophotometer (Beckman 
DU530). Phosphate buffer was used as a blank control. For ELISA standards the 
concentration of AFB1-lysine is determined using the extinction coefficient of Sabbioni 
(1990). i.e at pH 7.4 400nm ε = 30 866, at 346 nm ε =15821 at 257 nm ε = 16927 and at 
230 nm ε = 16200.  
Similarly AFB1-ova adduct was also analyzed spectrophotometrically and its 
concentration was estimated by Bradford method and readings were taken at 595 nm. 
Phosphate buffer was used as a blank. (Bradford, 1976; Detailed in section 3.9) 
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3.2.6. Evaluation of AFB1-lys adduct and AFB1-ovalbumin adduct in ELISA 
ELISA was performed typically as described in Waliyar et al. (2005a) with modifications 
as detailed here (ELISA buffer preparations given in Appendix). Antisera used for 
ELISA was produced in rabbits against AFB1-epoxide conjugated to BSA. Alkaline 
phosphatase conjugated anti-rabbit antibodies (AR-ALP) were used as secondary 
antibody and pNPP was used as substrate. The colorometric reaction was measured in an 
ELISA plate reader fitted with 405 nm filter. 
 
To determine the working concentration of AFB1-ova adduct, 100 µl of AFB1-ova 
adduct was coated to the ELISA plate, with a starting concentration of 100 ng to 0.78 ng 
ml-1 and incubated overnight at 4˚C. Plates were washed and blocked with blocking 
buffer and incubated for 1 hr at 37 oC. Then 100 µl of the antisera was added at 1:40,000 
dilution to each well and in subsequent step 100 µl of antirabbit antibody was added at 
1:2,000 dilution, then 100 µl of pNPP substrate at 1 mg ml-1 concentration was added and 
the colorometric reaction was read at 405 nm.       
 
To determine the working concentration of AFB1-lys, ELISA plates were coated with 
100 µl of 10 ng AFB1-ovalbumin adduct and incubated at 4˚C for overnight. Plates were 
washed thrice with washing buffer and blocked using the blocking buffer for 1 h at 37˚C. 
Then, plates were washed thrice and 100 µl of AFB1-lysine standards (serial dilutions 
starting from 2000 pg to 7.8 pg ml-1) prepared in PBS was added; and 50 µl of antisera 
against AFB1 epoxide (produced at ICRISAT) was added at 1:40,000 dilution and 
incubated for 1 hr at 37 oC. After washing the plates, 150 µl of antirabbit antibody (AR-
ALP) was added at 1:2,000 dilution, then 150 µl of pNPP substrate at 1mg ml-1 
concentration was added and the colorometric reaction was read in an ELISA plate reader 
fitted with 405 nm filter.   
 
Data was entered into XL software (Microsoft Office 2000) and regression analysis 
was done using software Sigma Plot V 2 (SigmaPlot Inc.) 
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3.2.7. IC-ELISA protocol  
Wells of the ELISA plates were coated with 150 µl of 10 ng/ml AFB1-ova in 0.2 M 
carbonate coating buffer, pH 9.6, and incubated overnight at 4°C. The wells were 
replaced with 0.2% skimmed milk in PBS containing 0.05% Tween-20 (PBST) to block 
free sites of the well. In each subsequent step, plates were incubated at 37°C for 1 hr 
followed by three washes with PBST. Hundred µl of AFB1-lys standards ranging from 
7.8 to 2000 pg/ml prepared in PBS were added in duplicate wells, and in the same wells 
50 µl of 1:40,000 antiserum (8th bleed) in PBST containing 1.5% BSA (PBST-BSA) 
were added. Sample wells consisted the same, except that, instead of the standard, 20 µl 
of hydrolyzed albumin (described below) in 80 µl of PBST was added. This was followed 
by addition of 150 µl of ALP-labeled anti-rabbit IgG at 1:2,000 in PBS. In the final step, 
1 mg/ml para-nitrophenyl phosphate in 10% diethanolamine buffer, pH 9.8, was added 
and plates were incubated at 37ºC for 1 to 3 hrs. Optical densities (OD) were read in an 
ELISA plate reader (Multiskan plus, Labsystems) fitted with 405 nm filter. Recordings 
were taken till OD values of the control well reached 1.5 ± 2.0 OD. The flow chart for the 
ELISA for testing of AFB1 in serum has given in Fig 9 and Standard ELISA template for 
estimating the AFB1-lys in serum samples is given in Fig 10. 
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Figure 9. Flow chart of indirect competitive ELISA for the estimation of AFB-lys in 
serum samples.  
 
ELISA plates were coated with 10 ng 1000 µl-1 of AFB1-ovalbumin conjugate diluted in 
coating buffer and incubated for two hours at 37°C. 
? 
Washed the antigen-coated plate with washing buffer three times and the wells were 
blocked with skimmed milk for 1 hour at 37°C 
? 
Washed and 100 µl of AFB1-lysine (7.8 to 2000 pg ml-1) in PBS was added to the 
standard wells and 80 µl of  PBS, 20 µl of sample against standard wells were added. 
Finally 50 µl of Antisera in PBS at 1:40, 000 dilution was added to all the wells and 
incubated for 1hr at 37°C with shaking. 
? 
Wash and 150 µl of alkaline phosphatase labeled anti-rabbit IgG at 1:2000 dilution was 
added and incubated for 1hr at 37°C. 
? 
150 µl of the substrate (p-nitrophenyl phosphate) in 10% diethanolamine was added to 
each well and the color development was read at 405nm in ELISA reader. 
 
The concentration of AFB1-lysine were calculated with the following formula:   
AxDxE   pg mg-1 albumin 
        G 
A= Concentration of AFB1-lysine in diluted or concentrated sample extract (pg ml-1) 
D= Times dilution with buffer 
C= Times concentration after clean up 
E= Extraction solvent volume used (ml) 
G= Sample weight (mg) 
 
 
 
 62
Figure 10. Standard ELISA template for estimating the AFB1-lys in serum samples 
 
 1 2 3 4 5 6 7 8 9 10 11 12 
A             
B* Standard 1 2 3 4 5 6 7 8 9 Control  
C Standard 1 2 3 4 5 6 7 8 9 Control  
D Sample X1 Y1 Z1 B3 N1 M4 L1 O1 P4 U2  
E Sample X1 Y1 Z1 B3 N1 M4 L1 O1 P4 U2  
F Sample  A1 A3 B1 B2 N2 M1 K1 O3 P3 H1  
G Sample A2 A3 B1 B2 N2 M1 K1 O3 P3 H1  
H             
 
Note: Edge wells (Rows A and H; and columns 1 and 12) were not used to avoid edge-
row effect on the data. Control wells consist of only antiserum but not AFB1-lys. 
 
Step 1: All wells of the plate were coated with AFB1-ova standard at 10 ng 100 µl-1  
Step 2: Plate was blocked with blocking buffer 
Step 3.1: AFB1 epoxide- lys standard (2000 pg to 7.8 pg 75 µl-1) and AFB1 epoxide 
antiserum (at 1:40,000) was added in the rows B and C (standards)  
Step 3.2: Samples (hydrolyzed albumin from test serum samples) and antiserum was 
added in rows D and E; and F and G. 
Step 4: AR-ALP (1:2000) was added into all the wells 
Step 5: pNPP substrate (1 mg ml-1) was added into all wells 
Step 6: ELISA readings were taken at 405 nm 
Step 7: Fed into computer. Absorbance values of standards were used for making a 
regression curve. From this, AFB1-lys concentrations in unknown samples were 
estimated.  
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3.2.8. High Performance Liquid Chromatography (HPLC) for validation of ELISA 
method (Sabbioni et al., 1990) 
HPLC were carried out using reversed-phase C18 column (Shimadzu Liquid 
Chromatography-LC-10AT VP) with a particle size 5 µm diameter linked to a 
fluorescence detector (Shimadzu RF-10 AXL). Solvent flow rate was 1 ml/min with 
mobile phase water:acetonitrile:methanol (70:17:17). Fluorescence detection parameters 
were set to excitation wavelength at 360 nm and emission wavelength at 440 nm. For 
each HPLC run, 20 µl of the hydrolyzed human serum albumin (HAS) was injected into 
the column and fractions were collected at 1 min interval. Each fraction was collected 
and dried in a vacuum evaporator and sample was reconstituted with 250 µl of PBS and 
analyzed in IC-ELISA.  
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3.3. Blood sample analysis for AFB1-lysine concentration 
3.3.1. Equipment and reagents  
• Microtitre plates – 96 well flat bottom plates, NUNC, Germany. 
• Spectrophotometer- Beckman DU530, Beckman Coulter, USA. 
• ELISA plate 96 well reader- Titrex Multiscan Plus 
• TLC plate- pre-coated size (20 x 20cm), particle size 2-25 m (Fisher Scientific). 
• Aflatoxin B1 standard (Sigma) 
• Ovalbumin (Sigma) 
• N-α-acetyl lysine (Sigma) 
• Meta chloroperbenzoic acid (MCPBA) (ICN, Biochemicals, Ohio) 
• Dichloromethane (DCM) (ICN, Biochemicals, Ohio) 
• Diethanolamine (Sigma) 
• P-Nitrophenyl Phosphate (pNPP) (Sigma) 
• Anti-rabbit antibody conjugated with alkaline phosphatase (AR-ALP) (Sigma) 
• General chemicals for buffer preparations were obtained from Sigma, BDH and 
Qualigens.  
• Rabbit polyclonal antiserum to AFB1 epoxide produced at ICRISAT (Anitha et 
al., 2011) 
• Preparation of buffers for ELISA are given in the Appendix (8.1) 
 
3.3.2. Sample selection:  
Control and case (patient) samples were selected from hospitals based on inclusion and 
exclusion criteria 
 
3.3.2.1. Criteria of inclusion: 
Controls: Subjects from the same family who do not have liver disease and consuming 
same lot of food that the patient consumes. Control samples were also collected from 
general population who do not have family history of liver disease or a history of any 
genetic disease that may lead to liver disease.  
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Cases: Patients who were diagnosed with liver disease (fatty liver, cirrhosis of liver, 
Hepatitis B, Hepatitis C, Chronic alcoholic and non alcoholic liver disease and 
hepatocellular carcinoma). 
 
3.3.2.2. Criteria of exclusion  
Controls: Subjects with the history of liver diseases. 
Cases: Patients who were not confirmed with the any liver disease.  
Insufficient blood sample or missing of the data of the subjects.    
 
3.3.3. Collection of blood sample 
Samples were collected from patients having various liver diseases including fatty liver, 
cirrhosis of liver, Hepatitis B, Hepatitis C, Chronic alcoholic and non alcoholic liver 
disease and hepatocellular carcinoma from several hospitals in Hyderabad, Andhra 
Pradesh. The control samples were collected from the individuals of the same family with 
no history of liver disease.  
 
Data of clinical and diet profile of each patient was documented using a form 
custom designed for the purpose (Annexure-I). All the objectives of the study were 
clearly explained to the subjects.  A signed consent on an Ethics Committee Approved 
form was obtained from patients willing to participate. The demographic data, including 
(i) age  (ii) family history of liver diseases (iii) habits like smoking, alcohol consumption, 
(iv) dietary profile and (v) clinical profile including liver function test, was obtained. 
 
After collecting the blood sample serum was separated from blood by placing the 
tubes in slant position for 60 min and centrifuged at 2,500 rpm for 10 min. Serum was 
collected into a separate tube and heat treated at 60 oC to inactivate viruses and any 
infectious agents. These were then stored at –20ºC until further use. After use, samples 
were autoclaved and discarded.  
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3.3.4. Isolation of albumin from serum (Modified from Chapot and Wild, 1991; 
Vinitketkumnuen et al., 1997).   
1. To the 500 µl of serum 750 µl of saturated ammonium sulphate was added drop 
wise. The mixture was vortexed and centrifuged in a Sorvall ss35 rotor at 9,000 
rpm at 4 °C for 15 minutes to precipitate immunoglobulins.  
2. Supernatant was collected and 100 µl of 1 M acetic acid was added to adjust its 
pH to 5, at this pH albumin precipitates from the serum. This was centrifuged at 
9,000 rpm at 4°C for 15 minutes to collect albumin. The supernatant was 
discarded and the precipitated albumin was redissolved in 1 ml of phosphate 
buffered saline (PBS, pH 7.4) and stored at –20 °C till its use. 
 
3.3.5. Estimation of protein concentration 
The concentration of albumin was estimated by the Bradford method (Bradford, 1976). 
Blank: To 1.8 ml of Bradford reagent 200 µl of PBS pH 7.4 was added. This was used 
for blank during spectrophotometric measurements. 
Sample: Five µl of albumin was diluted to 200 µl in PBS and to this 1.8 ml of Bradford 
reagent was added and mixed well. Readings were taken at 595 nm in a 
spectrophotometer. 
 
3.3.6. Albumin hydrolysis with Proteinase K (Modified from Chapot and Wild, 1991): 
Albumin was hydrolyzed into amino acids by digesting with proteiases.  
? Two mg of the albumin was digested with 0.67 mg of proteinase K in a total 
volume of 0.8 ml of PBS, pH 7.4 and incubated at 37 °C for 17-18 h.  
? To this, 10 mg BSA (from 100 mg ml-1 stock) was added to precipitate the 
undigested sample and proteinase K.  
? Proteins were subsequently precipitated by the addition of two volumes of cold 
ethanol.  The tubes were gently shaken for few minutes and incubated at -20°C 
for 2 h.  
? The precipitated proteins were removed by centrifugation at 5,000 rpm for 15 
min.  Ethanol was evaporated in a vacuum evaporator (Speed Vac Plus SC110, 
SAVANT, Refrigerated Vapor Trap RVT 400, SAVANT).  The final volume was 
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made up to 0.8 ml with PBS and stored at –20°C until use for the estimation of 
AFB1-lys adducts by ELISA.  
? Hydrolysis of albumin was confirmed by analyzing a fraction of digested sample 
by denaturing polyacrylaminde gel electrophoresis (12% SDS-PAGE, detailed in 
section 3.3.7). 
 
3.3.7. SDS-PAGE for digested albumin 
Undigested and digested albumin samples were analyzed by 12% SDS-PAGE  
(BROVIGA, mini slab gel electrophoresis apparatus). Procedure given by Kumar et al. 
(2004) was followed to prepare 12% resolving gel and 4% stacking gel (composition 
given in Appendix). Albumin and hydrolyzed samples were mixed with equal volumes of 
Lamelli buffer (Appendix) and kept in boiling water bath for 3 minutes and loaded into 
the wells of PAGE gel. After electrophoresis, gels were silver stained following the 
procedure given by  Kumar et al. (2004) (detailed in Appendix 8.3). 
 
3.3.8. Artificial spiking 
In order to assess the sensitivity of the albumin extraction and hydrolysis procedure, the 
albumin (2 mg) purified from healthy serum was artificially spiked with different 
concentrations of AFB1-lys. The sample was digested with proteinase K, as per the 
methods given in the section 3.3.6 and hydrolyzed sample was assayed in ELISA to 
estimate AFB1-lys concentration. 
 
3.3.9. ELISA for the AFB1-lysine spiked and digested albumin 
Artificially spiked samples and controls (hydrolyzed albumin from normal serum sample) 
were analyzed in ELISA as described in section 3.3.10.  
 
3.3.10. Testing of serum samples for AFB1-lys concentration using IC-ELISA 
The blood samples obtained from the various Hospitals in Hyderabad were used for 
analysis.  AFB1-lys and albumin were isolated from these samples and stored at –20ºC. 
Two mg of the protein from these samples were digested with 0.67 mg of proteinase K 
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and processed as mentioned in section 3.3.6.  These samples were stored at –20ºC. 
ELISA was performed as mentioned in section 3.2.7 with 20 µl of test sample per well.  
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3.4. Production of monoclonal antibody 
 
3.4.1. Equipment and reagents 
 
• Iscove’s Modified Dulbeccos Medium (IMDM) (Gibco BRL) 
• Fetal Bovine Serum (FBS)  (Gibco BRL) 
• L-Glutamine  (Glutamax-II, 200mM 100x) (Gibco BRL) 
• Mercaptoethanol (50 mM  1000x) 
• Penicillin (Sigma) 
• Streptomycin (Sigma) 
• Gentamycin (Sigma) 
• Nystatin (Sigma) 
• PEG 4000 (Merk) 
• HAT supplement (50X, Gibco BRL) 
• HT supplement (100X, Gibco BRL) 
• Membrane filters 
• CO2 incubator 
• Immunized BALB/c mouse,  
• Chloroform/ ether in a beaker with cotton 
• ethanol 
• Sterile blunt forceps and scissors (2 sets) 
• 100 mm petridish 
• Dissection pad with blotting paper and needles 
• Syringe 1 ml 5 ml and 10 ml glass 
• Needles 22G 
• Sterile centrifuge tubes 2x50ml 
• Eppendorf tubes 
• Adult healthy mouse 
• Glass syringe 10 ml 
• Dissection instruments (blunt forceps, scissors, dissection pad and needles) 
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• 96 well culture plates 
• ELISA plate (Nunc Maxisorb) 
• Aflatoxin B1 
• Keyhole Limpets Hemocyanin 
 
3.4.2. Immunization  
The immunogen Aflatoxin B1-Keyhole Limpets Hemocyanin (AFB1-KLH) conjugate 
(conjugate prepared using protocol given in section 3.1.2 by replacing BSA) was used to 
produce AFB1-KLH antibody. The immunogen was prepared and 250 µg of immunogen 
was emulsified with an equal volume of complete Freund’s adjuvant (Sigma). The 
primary injection was given subcutaneously to 6 of the six weeks old female Balb/c mice. 
The subsequent injection was given with the interval of 21 days with the same antigen 
prepared in Freund’s incomplete adjuvant. The mice were given rest for one month. Four 
days before fusion, an intraperitoneal booster dose was given with AFB1-KLH in PBS.  
 
The immunogen was injected at 21-day intervals. Only two injections were given 
to the mice. Mice were screened by an ELISA for specific serum antibody induction, and 
the mice with the best specificity were given an intraperitonial boost (2.5 mg) of 
conjugate, 4 days before their spleens were removed. 
 
3.4.3. Preparation of media 
Iscove’s Modified Dulbeccos Medium (IMDM) was used. It contains L-glutamine and 
25mM HEPES buffer. As per the manufacture instruction. 3.024 gm. of NaHco3/lit of 
medium was added during preparation.  
 
To 900 ml of sterile water one sachet of powder IMDM media and antibiotics -
penicillin (100 U/ml), gentamycin (50 µg/ml), and streptomycin (100 µg/ml) were added, 
stirred thoroughly and sterilized immediately by membrane filtration. Nystatin (5U/ml) 
was added after sterilization. As L-Glutamine is unstable, 2mM of glutamine (from 200 
mM stock) was added every 15 days to the medium. Prepared medium was stored in the 
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dark to prevent the production of highly toxic photoproducts. 10% and 20% IMBM were 
prepared for myeloma cell growth and hybrid cell growth using FBS.  
 
3.4.4. Preparation of myeloma cells: 
The myeloma cell line, Sp2/O was grown at 37C in 5% CO2 incubator. Cells were 
usually maintained in T25 flasks in 5 ml of 10% IMDM. When the cells were confluent, 
they  were diluted in fresh medium and distributed in additional flasks.Three days before 
fusion, the cells were split every day.  One day before fusion, the cells were split into the 
fresh medium supplemented with 10% IMDM. The growth of the cell was ensured to be 
in log phase before being used for fusion.  
 
3.4.5. Preparation of splenocytes 
Mice were sacrificed using chloroform. Then, they were placed on their backs for 
dissection.  The mouse was swabbed with 70% ethanol before incision. Immediately after 
cutting, the heart blood was collected quickly by making a single puncture. Then, the 
spleen was removed aseptically from the immunized mouse and placed in a 100 mm 
tissue culture plate. Using a 10 ml glass syringe fitted with 22G needle, the serum free 
IMDM media was injected into the spleen, such that splenocytes are seen coming out and 
become dispersed. This process was repeated several times to obtain the maximum 
number of the cells in the medium. The collection of cells was stopped once the spleen 
become pale in color. The medium containing dispersed cells was transferred to a sterile 
15 ml centrifuge tube leaving behind the tissue pieces. The cells were centrifuged at 
1,500 rpm (400g) for 10 minutes. The supernatant was discarded and the pelleted cells 
were washed by re-suspending it in 10 ml serum free IMDM medium.  
 
3.4.6. Counting the cells: 
After second centrifugation, pelleted cells were resuspended in 10% IMDM.  Then, 1:100 
dilutions of splenocytes were made with lysis buffer (Appendix) and left at 37˚C for 5 
minutes. After RBC lysis, the splenocytes were counted using a hemocytometer 
containing 16 square. 
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3.4.7. Preparation of macrophages (Feeder cells) 
The mouse was sacrificed using chloroform. First, the animal was washed with 70% 
ethanol. Then it was placed on its back for dissection. Using a blunt forceps and scissors, 
a small cut was made in the lower abdominal region and skin was removed to expose the 
peritoneum. Serum-free cold IMDM medium was injected as much as possible, from a 
single site. Then, without removing syringe, the abdomen of the mouse was taped in such 
a way that the tissue macrophages entered into IMDM medium. Then, the needle was 
withdrawn with the liquid completely, without any tissue. The liquid was transferred to a 
15 ml tube and centrifuged at 1,500 rpm (400g) for 10 minutes. The pellets were re-
suspended in 20% IMDM medium and counted using a hemocytometer.  
 
3.4.8. Fusion  
The hybridoma cells were derived from fusion between myeloma cells (Sp2/O cell line) 
and splenocytes of Balb/c mice immunized with AFB1-KLH. The technique for the 
production of hybridoma cells was similar to Galfre and Milstein 1981. The splenocytes 
and myeloma cells were mixed in a single glass tube in a ratio of 5:1. For 10x106 cells of 
spleenocytes 2x106 cells Sp2/O cell were used. This cell count was used for one culture 
plate. The number of culture plates used for fusion experiment varies according to the 
cell population. The excessive splenocytes  were stored in a freeze mix (Appendix) at -
80˚C. The splenocyte and myeloma cells mixed in a right proportion (5:1) were 
centrifuged at 1500 rev/min for 10 minutes. The supernatant was discarded and 0.5ml of 
pre-warmed PEG was added slowly over a period of 1 minute (0.1 ml for every 6 
seconds) by tapping the tube between each drop. In the following minute, the tube was 
tapped continuously allowing the cells to suspend completely in PEG. Then, 4.5 ml of 
serum free IMDM was added in 4 minutes to dilute the PEG. This was kept at 37˚C for 
20 minutes to 1hr. Then, the cells were centrifuged at 1500 rev/min for 10 minutes. The 
supernatants were discarded. The fused cells were then suspended in a complete medium 
containing 20% IMDM, 100X HAT, macrophages, 1000X mercaptoethanol. This was 
distributed in 96 well culture plates in such a way that each well received 200 µl of 
medium containing cells. As control, myeloma cells were added in 1 well in HAT 
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medium. They should all be dead in 4 days. The fusion experiment is briefly described in 
the Fig 11. 
  
3.4.9. Screening cells for antibody production 
After 12 day culture, supernatants from each well of the culture plate were 
analyzed using DAC ELISA. Culture supernatant from the cells that gave absorption of 3 
OD was transferred to 24 well culture plates in IMDM containing 20% FBS and 100X 
HT. The supernatants from 24 well culture plate were again tested by DAC ELISA. The 
clones which maintained absorption values over 1 were chosen for further selection. Cell 
suspensions from each well of the 24 well cultured plate were diluted to give 
approximately one cell per well when distributed into a 96 well culture plate. The plates 
were examined for the presence of number of hybridomas. Those that contained a single 
hybridoma in each well were retained and were screened for neutralization titers. 
 
3.4.10. DAC ELISA 
The ELISA plates were coated with 100 µl of AFB1-KLH conjugate per well in 
the concentration of 1µg/100 µl. After 1 hr incubation, 100 µl of culture supernatant were 
transferred to the ELISA plate. This was incubated for 1hr at room temperature and after 
washing, 100 µl of anti-mouse ALP conjugate was added in the concentration of 1:1000. 
This was incubated for 1 hr and finally 100 µl of 1mg/ml of PNPP substrate was added. 
Color development was observed and the read for optical density using ELISA plate 
reader at 405nm. 
 
3.4.11. Multiplication of selected hybridomas 
The cells were fed whenever the growth medium turned yellow by removing the spent 
medium with a pipette and replacing it with a fresh 20% IMDM medium. Spent medium 
containing monoclonal antibody was collected pooled and stored at -20˚C or at 4 ˚C  with 
0.02% sodium azide. 
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3.4.12. Cloning of hybridomas by limiting dilution 
Cell lines that were positive in the DAC ELISA screenings were transferred to individual 
5 ml culture flasks. These cells were grown in CO2 incubator and screened again by 
ELISA for its antibody activity. The antibody in a supernatant was collected in a tube and 
stored as mentioned above the cells were scraped and centrifuged at 2000 rev/min for 5 
minutes. The cell suspension in freezing medium was dispensed at 0.5ml per freezing 
vial. These vials are stored at -80˚C.  
 
3.4.13. Determination of specificity of monoclonal antibodies (MAbs) 
To evaluate the cross reactivity of each of the monoclonal antibodies, it was essential to 
determine the optimum condition for neutralization. These included coating antigen 
(AFB1-BSA) concentrations and the dilution of the antibody required for neutralization. 
Antibody titers were determined by the indirect competitive ELISA procedure described 
in the section 3.2.7. The optimum concentration required in each step to obtain the 
maximum sensitivity was determined by 50% displacement values of B/B0, where B is 
the extinction of the well containing AFB1 and B0 is the extinction of the well without 
toxin, derived from the slope of calibration curves. Using these parameters, dilutions of 
(50µl/well) of monoclonal antibodies were added to 100 µl of AFB1-BSA, at dilution 
ranging from 1:500 to 1:20,000. The protocol used for the characterization of antibody 
specificity was similar to those employed for the characterization of polyclonal 
antibodies. 3.1.7.1 and 3.2.7. 
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Figure 11. Fusion experiment 
      Day   1        
 
     In four days all sp2/o cells die 
     Clones hybridize 4-16 celled stage 
      
       
     Change medium HT after 8 days 
 
  
Around 40% confluent Hybridoma 
12-15 At this stage immuno-assy can be done 
to select +ve clones 
 
Pick up +ve clones to 24 wells plates (1ml) 
 
 
3-4 days >50% confluent (ELISA)  (0.5% ml) 
 
 
Flasks 5 ml the cells are cultured + ve stable 
 
 
Sub culture & freeze cells 
 
 
Check ELISA Parent clones  
 
 
Monoclonals 
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3.5 Detection of p53 Mutation using Restriction Fragment 
Length Polymorphism (RFLP)   
3.5.1. Equipment and reagents  
• DNA extraction kit (Nucleospin) 
• Horizontal electrophoresis apparatus (Geni) 
• Thermocycler (Applied Biosystems) 
• UV illuminator 
• PCR reagents (Biorad) 
• Primers (Sigma) 
• All the chemicals for electrophoresis were procured from Sigma 
 
3.5.2. Sample collection  
One hundred thirty blood samples were collected from Hepatitis B surface antigen 
positive patients. These samples were obtained from Global hospitals and Apollo 
hospitals, Hyderabad, India. In addition, 108 samples were also collected from healthy 
people to use them as controls in the analysis. Sample selection, criteria of inclusion and 
criteria of exclusion is given in sections 3.3.2, 3.3.2.1 and 3.3.2.2 respectively. All of the 
patients were permanent residents of Andhra Pradesh and adjoining states of south India. 
For the extraction of DNA, 0.5 ml of blood samples was collected in EDTA vial. Samples 
were immediately transferred to ICRISAT’s “Mycotoxicology and virology lab, 
Hyderabad under refrigerated condition. Then samples were stored at -70ºC for further 
use.  
 
3.5.3. Extraction of DNA from blood sample 
DNA was extracted from 200 µl of blood using Nucleospin kit as per manufactures 
protocol and stored at 4ºC until polymerase chain reaction (PCR) performs. The protocol 
for the extraction of DNA is as follows. 
 
1. Blood samples were lysed by the addition of 25 µl of proteinase K and 200 µl of 
blood into 1.5 ml microfuge tubes 
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2. 200 µl of lysis buffer B3 was added to the samples and vortexed the mixture 
vigorously for 10 seconds 
3. Samples were incubated at 70ºC for 10-15 minutes 
4. 210 µl of ethanol was added to each sample and vortexed. 
5. Nucleospin Blood column was placed in a 2ml centrifuge tube and loaded the 
sample and centrifuged for 1 min at 11,000g.  
6. The flow through was discarded with collecting tube. 
7. Blood column was then placed in to a new 2ml collecting tube and 500 µl of 
buffer BW was added and centrifuged for 1 min at 11,000g then collecting tube 
was discarded with flow-through. 
8. Blood column was again placed in to a new collecting tube and 600 µl of buffer 
B5 was added and centrifuged for 1 min at 11,000g then discarded the flow-
through. 
9. Column was again kept in a same collecting tube and centrifuged for 1 min at 
11,000g to dry the column. 
10. The column was then placed on 1.5 ml microfuge tube and 100 µl of pre-warmed 
elution buffer BE (70ºC) was dispensed directly on to the silica membrane and 
incubated for 1min at room temperature then centrifuged for 1min at 11,000g. 
11. DNA in elution buffer was collected and stored in -20 until use. 
 
3.5.4. Agarose gel electrophoresis 
The genomic DNA was analysed by 2% agarose gel electrophoresis using 
horizontal gel electrophoresis system. A gel slab of required size containing 2% agarose 
and 6µl of 10mg/ml ethidium bromide was prepared in 1x TBE using gel mould. After 
setting time of 20 min the gel mould was placed in a tank containing sufficient quantity 
of 0.5x TBE buffer (Appendix 8.5). The DNA along with DNA Marker (λ DNA Marker; 
Roche, Cat# 528 552) was loaded in wells of 2% agarose gel and electrophoresed at 
100V for 1-2h. Removed the gel from the tray and visualized on a UV-transilluminator 
and photographed with a PolaroidR camera fitted with a UV filter. 
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3.5.5. Optimization of PCR condition 
After DNA extraction from blood samples PCR was carried out in Applied 
Biosystems thermocycler. The thermal cycles of the reaction were standardized by 
performing the PCR at various combinations of denaturation, annealing, and extension 
temperatures according to the Tm of the degenerate primers. We focused on the analysis 
of codon 249 by amplifying a region of exon 7 surrounding codon 249 using forward 
(p53Fser: 5’CTT GCC ACA GGT CTC CCC AA 3’) and reverse (p53Rser: 5’AGG GGT 
CAG RGG CAA GCA GA 3’) primers. The temperature profile followed for 
amplification of p53 exons was initial denaturation at 94°C for 2 minutes followed by 35 
cycles of 94°C for 30 seconds, 60°C for 30 seconds, and 72°C for 30 seconds, and a final 
extended synthesis at 72°C was performed for 5 minutes. DNA Marker (λ DNA Marker; 
Roche, Cat# 528 552) was used to determine the size of PCR amplified product. Gel was 
stained with ethidium bromide (0.5µg/ml), viewed on a UV-transilluminator and 
photographed with a polaroidR camera fitted with a UV filter.  
 
The PCR reaction mixture was standardized as follows: each 50 µl reaction 
mixture consists the following components: 
Components Single reaction with total volume of 50 µl
10x  PCR reaction buffer 5 µl 
MgCl2 (25mM) 3 µl 
Forward primer (10pm/µl) 2 µl 
Reverse primer (10pm/µl) 2 µl 
Taq polymerase (2.5U) 0.5 µl 
dNTPs mixture (100mM) 1 µl 
Template DNA (50-60ng/µl) 2 µl 
Double sterile distilled water 34.5  µl 
Total volume 50 µl 
 
3.5.6. Purification of PCR products 
To obtain enough amounts of DNA fragments for further testing, 1 µl of PCR product of 
each sample was picked up as template to have another 4 PCR reactions with the same 
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amplifying conditions. The PCR products were then purified as follows: 
• To each 250 µl of PCR product, equal volume of phenol:chloroform was added 
and then centrifuged at 13,000 rpm.  
• Supernatant was taken into another tube and equal volume of ethanol was added 
and kept for precipitation at -70°C for 1 hr.  
• Then centrifuged at 13,000 rpm and pellet was kept for drying at 37°C for 10 min. 
• 25µl of milli Q water was added to dissolve the pellet and stored at -20ºC for 
further applications. 
 
3.5.7. Restriction Fragment Length Polymorphism (RFLP) 
The 254 bp of purified DNA fragment, derived from exon 7 of p53 gene, was subjected 
to restriction enzyme Hae III (New England Biolabs Company) digestion. The restriction 
enzyme digestion reaction system consists of 1.3 µl HaeIII, 2 µl 10×buffer, 6 µl PCR 
product, 0.7 µl ddH2O. These reaction mixtures were kept in the incubator at 37ºC for 1 
hour. Enzyme Hae III cleaves a GG/CC sequence at codons 249-250, generating 92bp, 
66bp and several small fragments from the 254 bp purified DNA product of the PCR 
reaction. If there is a mutation at codon 249-250 resulting in an uncleaved, 158bp 
fragment, and this feature will be distinguished from that of normal samples on 2 % 
agarose gel stained with ethidium bromide. Absence of the band at 254 bp (full-length 
PCR products) provides a control for complete digestion of the PCR product.  
 
3.5.8. Statistical analysis 
Pearson’s chi-square and Fisher’s exact test were used to assess statistical significance of 
frequency tables of independent variables and 249 Ser mutations with 95 %  confidence 
intervals (CI) using the software SAS 9.2V to estimate the risk of mutation among the 
study groups considering age, gender, hepatitis B surface antigen status and aflatoxin B1 
positive status in ELISA as potential confounders.  
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4. RESULTS 
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4.1 Production and characterization of polyclonal antibody 
4.1.1. Immunization of rabbit 
The immunization protocol followed in this experiment was good enough to elicit the 
immune response. The antibody obtained from rabbit serum was further characterized as 
indicated in the following sections. 
 
4.1.2. Monitoring antibody titer  
The titer of each bleed of antiserum was determined by IC-ELISA performed in 96-
well microtiter plates (Maxi-sorp, Nunc). The procedures used in this study have 
contributed to the production of high titered and specific antiserum against AFB1-lys, 
and high yields of synthetic AFB1 adduct necessary as standards. Titer of the antiserum 
prior to booster immunization was between 1:2,000 to 1:10,000 and titer of antiserum 
post-booster injection was 1:40,000 to 1:75,000, suggesting positive effect of longer 
resting time and booster dose on improving the antiserum titer. Antiserum, used after 
cross absorption with 1.5% BSA, did not cross-react with carrier proteins, 10 mg/ml BSA 
or ovalbumin in PBS. Eighth batch antibody that had a titer of 1:40,000 was used in 
subsequent experiments. The optimum antiserum dilution required to obtain the 
maximum sensitivity was determined by 50% displacement values of B/B0, where B is 
the OD of the well containing AFB1-lys, and B0 is the OD of the negative control, using 
various dilutions of the antibody was added to 100 µl of the AFB1-lys dilutions ranged 
from 2000 pg/ml to 7.8 pg/ml. This demonstrated that antiserum diluted at 1:40,000 can 
detect up to 5 pg AFB1/mg HSA.  
 
4.1.3. ELISA for detecting cross reaction  
Specificity of the antiserum determined by DAC-ELISA mentioned in 3.1.7.1 and IC-
ELISA mentioned in 3.2.7, except by replacing AFB1-lys with BSA and ovalbumin 
demonstrated lack of antibody cross reaction with carrier proteins (Fig. 12).  
 
 
 
 
 82
Figure 12. Evaluation of polyclonal antibodies (1:40,000 v/v) against AFB1-lys, BSA 
and ovalbumin in IC-ELISA.  
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4.2 Standardization of ELISA method to detect AFB1-lysine 
and validation of ELISA method developed  
4.2.1. Preparation of AFB1-lys and AFB1-ova adducts  
AFB1-lys adducts showed two peaks, one at 275 nm and other at 340 nm which was 
detected by spectrophotometer reading from 200-400 nm (Fig. 13). The concentration of 
the adduct was 55.5 µg ml-1, which was calculated as mentioned in section 3.2.5. The 
concentration of AFB1-ovalbumin determined by spectrophotometer reading at 595 nm 
using Bradford method was 4.8 mg ml-1 (Fig. 14). The AFB1-ovalbumin and AFB1-lys 
adduct was aliquoted into 0.2 ml tubes and stored at –20 oC.  
 
TLC analysis confirms the presence of AFB1-lys adduct and AFB1-ova adduct which 
showed a single fluorescence spot at the base of the plate with an Rf value equal to zero 
and there was no free AFB1 present in the aqueous phase (Figs. 15 and 16). Standard 
AFB1 showed single fluorescence spot at the top. The organic phase showed multiple 
fluorescence spots indicating the presence of unreacted AFB1 and its derivatives.   
 
4.2.2. Evaluation of AFB1-lys and AFB1-oval adducts 
ELISA performed to evaluate the AFB1-lys and AFB1-ova adducts as detailed in 3.6. 
The detection limit of AFB1-lysine for antiserum was found to be 7.8 pg ml-1. Therefore, 
for competitive ELISA AFB1-lys standard was used from 2000 to 7.8 pg ml-1 as working 
concentration. At this concentration standards gave regression of 0.994 (from three 
experiments). The regression curve for AFB1-lys was shown in Fig 17.  
 
To determine the AFB1-ova adduct concentration, it was tested from 100 ng - 0.78 ng 
ml-1 in ELISA. After 10.0 ng ml-1 there was no variation in absorbance values measured 
at 405 nm. AFB1-ova concentration of 10 ng ml-1 was found to be best suited for 
competitive ELISA.  
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Figure 13. Spectrophotometric graph of AFB1-lys adduct taken from 200-400 nm. 
This shows one peak at 275 nm and the other one at 340nm.    
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Figure 14. Spectrophotometric graph of AFB1-ova from 200-400 nm shows Note two 
peaks, one at 275 nm and the other one at 365 nm with multiple minor peaks. 
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Figure 15. TLC to evaluate AFB1-lysine adduct formation 
1         2       3       4        5        6         7       8      9 
Lane 1, AFB1 standard 20 µl 
Lane 2, AFB1 lysine 20 µl  
Lane 3, AFB1 lysine 40 µl 
Lane 4, AFB1 lysine 60 µl  
Lane 5, DCM fraction 20 µl 
Lane 6, DCM fraction 40 µl 
Lane 7, DCM fraction 60 µl 
Lane 8, Lysine 10 µl 
Lane 9, Lysine 20 µl l 
 
Note that, AFB1 fluoresces under UV light. AFB1-lys adduct has no relative 
mobility and therefore the fluorescence appears at the spot (lanes 2, 3 and 4); 
lysine lacks fluorescence (lanes 8 and 9); and multiple spots in organic phase 
(lanes 5, 6 and 7) suggests the partial reactants, unreacted AFB1. 
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Figure 16. TLC to evaluate formation of AFB1-ovalbumin adduct  
1        2        3      4       5        6       7       8 
Lane 1. AfB1 standard 10 µl 
Lane 2. AfB1 standard 20 µl 
Lane 3. AfB1-oval adduct 10 µl 
Lane 4. AfB1-Oval adduct 10 µl 
Lane 5. Organic phase 10 µl 
Lane 6. Organic phase 20 µl 
Lane 7. Oval standard 10 µl 
Lane 8. Oval standard 20 µl 
 
 Note that AFB1-ova adduct has no relative mobility and therefore the 
fluorescence appears at the spot (lanes 3 and 4); ovalbumin lack of fluorescence 
(lanes 7 and 8); and multiple spots in organic phase (lanes 6 and 7) suggests the 
partial reactants, unreacted AFB1. 
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Figure 17 Regression curve plotted using ELISA absorbance values of AFB1-lys 
standards measured at 405 nm  
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4.2.3. Validation of IC-ELISA using HPLC 
Results of IC-ELISA were compared with HPLC carried out using reversed-phase C18 
column. Two peaks were obtained in HPLC, one major peak at 2.0 min corresponding to 
AFB1-lys and one minor peak at 2.4 min (Fig 18), suggesting that AFB1-lys had a relative 
retention time of 2 min. Each fraction was collected and dried in a vacuum evaporator 
and sample was reconstituted with 250 µl of PBS and analyzed in IC-ELISA. Results 
revealed high correlation in AFB1-lys estimates by HPLC and IC-ELISA (SD±1.7 to 
17.8) (Table 6). HPLC analysis of albumin samples hydrolyzed and purified with Sep-
Pak cartridge (Fig 18A) or ethanol (Fig 18B) gave similar results (Table 6). 
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Table 6. Quantitative estimation of AFB1-lys in human serum albumin by HPLC 
and in HPLC fraction by IC-ELISA 
 
Concentration of AFB1-lys (pg/mg) Sample No. 
HPLC IC-ELISA 
% recovery of AFB1-lys 
in HPLC fraction by IC-
ELISA  
1a 72 69.53 96.5 (±1.7) 
1b 72 67.2 93 (±3.4) 
2b 109.08 103 94.2 (±4.3) 
3b 101 75.82 75.0 (±17.8 
4b 
(negative control) 
0c -c - c 
aHydrolyzed sample purified with Sep-Pak cartridge; aHydrolyzed sample purified by 
ethanol precipitation; CNo peak in HPLC; OD equivalent to negative control in ELISA) 
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Figure 18. Reversed phase HPLC of proteinase-K hydrolyzed human serum 
albumin spiked with AFB1-lys. Sample purified using Sep-Pak cartridge (A) and 
purified with ethanol precipitation (B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
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4.3 Sample analysis 
4.3.1. Albumin hydrolysis  
The concentration of the albumin obtained was approximately 12 mg 500 µl-1 of serum.  
Figure 19 shows the purity of albumin extracted from serum and it also shows the 
complete digestion of albumin with proteinase K enzyme. The Lane 1 shows Protein 
standards (MBI Fermentas, Cat# SM0441), Lanes 2-5 shows albumin extracted from 
human serum, Lane 6 shows Albumin artificially spiked with AFB1-lys and hydrolyzed 
with proteinase K, Lane 7-10 shows albumin hydrolyzed with proteinase K and Lane 11, 
shows Proteinase K. 
 
4.3.2. Testing of recovery of AFB1-lysine in artificially spiked albumin sample 
The artificial spiking experiment revealed 96±11% recovery of the AFB1-lys in IC-
ELISA (Table 7). Comparison of efficacy of albumin hydrolysis using ethanol 
precipitation procedure and Sep-Pak cartridges found no significant differences, 
indicating that low-cost ethanol precipitation approach is effective (Table 8). 
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Figure 19. Separation of purified albumin and hydrolyzed albumin in 12% SDS-
PAGE and the gel was stained with silver nitrate to visualize the proteins 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lane 1, Protein standards (MBI Fermentas, Cat# SM0441) 
Lanes 2-5, Albumin extracted from human serum  
Lane 6, Albumin artificially spiked with AFB1-lys and hydrolyzed with proteinase K 
Lane 7-10, Albumin hydrolyzed with proteinase K 
Lane 11, Proteinase K 
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4.3.3. Indirect competitive ELISA for estimating the concentration of AFB1-lysine 
adduct in serum samples 
IC-ELISA developed shows the regression of 0.99 for the standards (7.8 to 2000 pg ml-1) 
(Fig. 17). The AFB1-lysine concentration in samples was expressed in pg mg-1 of 
albumin in positive samples with mean aflatoxin-albumin adduct level of 86 samples are 
181.9 ± 5 and SD 1.49 ± 7. AFB1-lys was detected in 86 samples at a concentration 
between 2.5 to 677 pg mg-1 albumin (Table 9; Table 11; Master chart 1). All the samples 
that were positive to AFB1-lys were from HBV positive subjects, indicating a potential 
risk of HCC in 12.7% of the 673 subjects tested in this study.  
 
Mean aflatoxin-albumin level according to gender, HBV infection, socioeconomic 
status and age is given in Table 10. The presence of hepatitis B and aflatoxin B1 together 
increases the severity of liver diseases which is represented by pb value 0.039 (<0.05). 
The mean afltoxinB1-albumin adducts level in hepatitis B positive patients are 202.0 with 
95% confidence interval of (158.4-245.7). Where as the mean adduct level in control 
samples are 105.8 with 95% confidence interval of (35.04-176.6). These control samples 
are collected from the same family members who consume same lot of food but they 
clinically don’t have any symptom of liver disease at the time of collection of samples. 
There is no significant difference in mean aflatoxin-albumin level according to age, 
socioeconomic status and gender.  
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Table 7. Percentage recovery of AFB1-lys from spiked human serum albumin by IC-
ELISA 
 
Concentration 
estimated by IC-
ELISA (pg/mg) 
% recovery* Sample 
no 
AFB1-lys spiked in 
human serum albumin 
(pg) 
Expt.1 Expt. 2 Expt. 1 Expt. 2 SD (±) 
1 2000 1677 1832 83.8 91.6 5.5 
2 1000 1049 979 104.9 97.9 4.9 
3 500 556 483 111.2 96.6 10.3 
4 200 189 212 94.5 106 8.1 
5 50 51.38 52.85 102.7 105.7 2.1 
*(Concentration estimated by IC-ELISA/amount of AFB1-lys spiked) × 100 
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Table 8 Effect of hydrolyzed albumin purification method on AFB1-lys detection in 
IC-ELISA.  
 
AFB1-lys recovered (pg/mg)* Sample 
No. 
Concentration of 
AFB1-lys spiked in 
HSA (pg/mg) Sep-Pak cartridge
a  Ethanol purificationa 
1 0 -b - 
2 0 - - 
3 0 - - 
4 0 - - 
5 50 46.12 (92%) 47 (94%) 
6 200 189.76 (94%) 212.50 (106%) 
7 1000 1038.5 (103%) 1049.29 (104%) 
*HSA=human serum albumin (Sigma). 
aMethod used for purification after albumin hydrolysis.  bOD values ≤negative control.0 
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Table 9. Estimation of AFB1-lys in human serum albumin by IC-ELISA 
  
AFB1-lys adduct concentration  
(pg/mg albumin)a 
Number of samples 
- b 587 
<100 38 
100-500 42 
500-1000 6 
Total 673 
aAlbumin purified from serum fraction was hydrolyzed with proteinase-K, purified by 
ethanol and tested in IC-ELISA in duplicates. bOD equivalent to negative control in 
ELISA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 98
Table 10. Mean afaltoxin B1-albumin according to gender, HBV infection and 
socioeconomic status. 
 
 
Parameter           Mean aflatoxin level                   p value                                 95% CI               
  
Gender 
     Female                   164.8                                   0.602                            88.9-240.7 
     Male                      187.8                                                                      142.9-232.7 
Hepatitis B 
     Negative                105.8                                   0.039                            35.04-176.6 
     Positive                  202.0                                                                      158.4-245.7 
Socio economic status 
      Poor                      150.8                                                                     101.7-199.9 
      Middle                   206.5                                 0.15                            150.2-262.8       
      Rich                          -       
Habits      
Alcoholic                    140.9                                  0.44                              53.89-227.9 
Non-alcoholic             187.3                                                                     145.5-229.1             
                  
Age  
35-40                           122.25 
40-45                           173.51 
45-50                           218.18  
50-55                           145.19 
55-60                           174.09                              0.69 
               
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 99
Table 11. Concentration of AFB1-lysine pg mg-1 albumin  
S.No Concentration of AFB1-lysine pg mg-1 albumin 
(values from two experiment) 
Standard Deviation 
 
1 31.5 0.7 
2 129 0 
3 111 1.4 
4 676.5 4.9 
5 403.9 5.6 
6 180.8 1.2 
7 249.1 5.3 
8 393.4 4.9 
9 153.1 0.2 
10 208.4 0.7 
11 68.7 0.9 
12 597.5 3.5 
13 164.6 0.4 
14 318.2 2.4 
15 54.5 2.1 
16 26 2.8 
17 58.5 2.1 
18 27.5 2.1 
19 32.9 1.5 
20 115.1 1.2 
21 186.2 5.3 
22 30.7 1.0 
23 121.4 2.1 
24 73.3 6.6 
25 83.7 7.4 
26 119.4 0.8 
27 169.7 7.4 
28 129.5 0.7 
29 114.2 1.0 
30 132 4.2 
31 57.5 0.7 
32 38 0 
33 110 0 
34 33.75 3.1 
35 185.85 5.8 
36 43.1 4.1 
37 118.4 0.6 
38 250.6 7.5 
39 116.0 5.5 
40 547 4.2 
41 466.5 3.5 
42 117.1 4.0 
43 419.5 9.1 
44 394.5 7.7 
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S.No Concentration of AFB1-lysine pg mg-1 albumin 
(values from two experiment) 
Standard Deviation 
 
45 257 4.2 
46 438 0 
47 27.5 2.1 
48 33 4.2 
49 330 7.0 
50 121.5 4.9 
51 603.5 4.9 
52 286 0 
53 42 0 
54 229 1.41 
55 19.5 0.7 
56 343 2.8 
57 36.5 0.7 
58 450 0 
59 79.5 3.5 
60 25.5 0.7 
61 57.5 2.1 
62 29.5 0.7 
63 76 4.2 
64 438 2.8 
65 622.5 3.5 
66 283.5 4.9 
67 617.5 3.5 
68 234 2.8 
69 322.5 3.5 
70 41 0 
71 52.5 0.7 
72 74.1 1.4 
73 2.75 0.2 
74 593.5 0.7 
75 41 0 
76 25 0 
77 49 0 
78 14 1.0 
79 9.1 0.2 
80 77.2 0.3 
81 34.5 0.7 
82 114.6 0.5 
83 112.5 0.5 
84 91.7 0.3 
85 90.5 0.6 
86 159.6 3.2 
 181.9* 1.49†† 
 
*Mean AFB1-lysine 
††Mean standard deviation 
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4.4 Production of monoclonal antibodies 
4.4.1. Immunization 
The immunization protocol followed in this experiment was good enough to elicit the 
immune response. The sera from mice immunized with 21 days protocol showed good 
antibody response. The mice selected for fusion showed AFB1-KLH polyclonal antibody 
titer 1:10,000.  
 
4.4.2. Fusion and cloning 
The fusion efficiency (number of wells showing cell multiplication in each well of 96-
well plate) was 80%. The cells derived from 15 wells showed specific binding to 
Aflatoxin-BSA adduct. But after two successive transfers only one retained the antibody 
activity. The growing hybridoma cells are shown in fig 20. 
 
4.4.3. Titer and characterization of antibody 
The titer of antibody was found to be 1: 5000. The antibody was highly specific for 
AFB1-BSA adduct. There was absolutely no cross reaction with BSA,Ovalbumin and 
Human serum albumin. The designation, cross reactivity and minimal inhibition values 
for monoclonal antibody (IG8) that showed high specificity to AFB1-BSA is presented in 
Table 12. It has the detection range from 1 µg to 4 ng ml-1 with 50% inhibition at 0.13 µg 
ml-1. The dose response curve of AFB1-BSA is given in Fig 21. 
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Table 12.  Cross reaction and minimal inhibition value of clone 1G8 
 
 
 
Designation                      Cross reaction (%)                         Minimum inhibition (µgml-1) 
                       
___________________________________________________________ 
          AFB1-lysine  AFB1-BSA   BSA   Ovalbumin HSA              AFB1-lysine 
  
 
1G8           100             100           0          0             0                     0.004                            
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Figure 20.  Growing hybridoma cells produced against AFB1-KLH conjugate on 
7th day. 
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Figure 21. Dose response curve of aflatoxinB1-BSA. Fifty percent inhibition value of 
AFB1-BSA was 0.13 µg ml-1. 
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4.5 Detection of p53 Mutation using Restriction Fragment 
Length Polymorphism (RFLP) 
 
4.5.1. DNA extraction 
DNA was extracted from whole blood using neucleospin kit as detailed in the Section 
3.5.3. This resulted in good quality DNA from all 238 samples. The genomic DNA was 
used for PCR amplification as detailed in the Section 3.5.5, using the forward and reverse 
primers which yielded 254 bp amplicon (Fig 22). 
 
4.5.2. Restriction Fragment Length Polymorphism (RFLP) 
The RFLP result indicates that the absence of mutation at codon 249 results in 92 bp, 66 
bp and several small fragments; whereas mutation at the codon 249 eliminates the Hae III 
restriction site resulting in undigested amplicon and 158 bp fragment (Fig 23).  
 
A totally of 238 samples were analyzed for p53 gene mutation. Subject age 
ranged from 36 to 61 years, 64% of them were men, 130 were Hepatitis B virus (HBV) 
positive and 108 were negative to HBV. Among 130 HBV positive samples 112 samples 
are having cirrhosis of liver. The p53 mutation was detected in 10 (4.2%) samples,  8 of 
which were from HBV positive subjects and also positive for aflatoxin-albumin adduct (p 
= 0.07); Remaining two were from HBV negative subjects, but positive to aflatoxin-
albumin adduct (p = 0.14).  
 
In total 37 of 238 samples analyzed tested positive to aflatoxin-albumin adduct in 
IC-ELISA. The concentration of aflatoxin adduct ranged from 2.5 to 677 pg mg-1 of 
albumin (Master chart 2). Among these, 29 samples were HBV positive and 8 samples 
were positive to both HBV and p53 mutation (p=0.07). The Chart 1 shows the 
relationship between p53 mutation and aflatoxin-albumin positivity. At 10% level of 
significance if probability <0.1 then presence of aflatoxin-albumin adduct and p53 
mutation are dependent, otherwise independent (Table 13; Fig 24). This shows that p53 
mutation and aflatoxin-albumin adduct positivity are dependent in HBV samples. We 
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found there was no significance in the 249ser mutation between females with HBV 
(p=0.12) and males with HBV (p=0.38). This shows gender has no influence on aflatoxin 
induced p53 mutation.  
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254 bp 
100 bp DNA Ladder 
   1        2     3     4        5      6      7        8     9     10 Lanes 
Figure 22. The electrophoresis map of PCR products 
Representative ethidium bromide stained 2 percent agarose gel containing undigested 
PCR products (lanes 2-9 ), Lane 1and 10 shows 100bp DNA ladder, which was used  
as a size marker. 
107 
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254 bp  158 bp 
99 bp 
66 bp 
Hae III + 
p53 mutation 
Representative ethidium bromide stained 2 percent agarose gel containing undigested PCR products 
(lanes 2and 6 ), PCR products digested with Hae III ( lanes 3,4,5,7,8 and 9) ,lane 3,4 and 5 shows  p53 
mutation, lane 7,8 and 9 shows  wild type. Lane 1and 10 shows 100bp DNA ladder, which was used as a 
size marker. 
- 
      1      2      3     4      5     6     7    8     9     1 0 Lanes 
- - + + UD UD M M 
Figure 23. The electrophoresis map of RFLP 
100 bp DNA Ladder 
 109
Table 13. Demographic Data on Patients with hepatitis B 
 
 
Parameter           No of subjects analyzed       p53 mutation     Aflatoxin-lys         p value   
                                      (n=238)                            (%)                         (%) 
  
Serum Hepatitis B 
     Positive                    130 (54.6)                    8(6.1)             29(22.0%)            0.14 
     Negative                   108 (45.4)                    2(1.8)              8(7.4%)               0.07  
Sex 
     Male                           
 
Hepatitis B Positive         88(57.5)                    7(7.9)            24(27.2)                0.38 
 
Hepatitis B Negative       65(42.4)                   2(3)                  7(10.7)                0.21                                         
     
     Female                        
 
Hepatitis B Positive         42(49.4)                   1(1.17)              5(5.8)                 0.12                                         
 
Hepatitis B Negative       43(50.5)                     0(0)                  1(1.17)                 --                                           
 
               
 
 
Note: ' - ' means Row or column sum zero. No statistics is computed. 
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Figure 24 comparative studies of p53 mutation and aflatoxin B1 in case and control 
samples.  
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5. Discussion 
Many crops and commodities are vulnerable to attack by a group of fungi that are able to 
produce toxic metabolites called mycotoxins. There are three major genera of fungi that 
produce mycotoxins: Aspergillus, Fusarium and Penicilium. Of these, toxins produced by 
A. flavus and related species are most potent. They are referred to as aflatoxins. Several 
types of aflatoxins occur in nature. Of these, AFB1 has been recognized as the most 
potent toxin. It has been classified as a carcinogen. They enter into human and animal 
systems through consumption of contaminated food. Although food safety regulations 
have been established in most countries to regulate the levels of toxin within prescribed 
limits in food and feed, the implementation of these regulations is poor in developing 
countries.  As a consequence, populations, especially from economically poorer sections, 
are most vulnerable to aflatoxin exposure. Thus, AFB1 poses a serious health threat to 
individuals in many underdeveloped countrie where this mycotoxin is present in staple 
foods (Detroy et al., 1971; Groopman et al., 1988).  
 
Most of the interest in AFB1 has been in the area of liver cancer and genotoxicity 
(Busby and Wogan, 1984; Groopman et al., 1988). The major reaction in AFB1-
metabolism is relatively well established (Fig. 2). CYP450 oxidizes AFB1 to AFB1-8,9 
endo and exo epoxide. Only the exo epoxide can bind to DNA and protein (Guengerich et 
al., 2002). Epidemiological studies provide strong evidence of an association between 
chronic HBV infection and primary hepatocellular carcinoma (Beasley et al., 1981; 
Beasley, 1987). However, other types of exposure are known to play a role in the 
pathogenesis of liver cancer. In populations with a high prevalence of HBV infection, a 
relationship has been observed between mortality from primary hepatocellular carcinoma 
and dietary AFB1 exposure (Van Rensburg et al., 1985; Peers et al., 1987; Yeh et al., 
1989). It is not yet clear whether AFB1 exerts its carcinogenic effect in individuals in the 
absence of chronic infection with HBV (Wild et al., 1990). However, AFB1 has been 
shown to be a carcinogen in many species.  Human liver cells have been shown to be 
capable of metabolizing AFB1 in vitro to the biologically reactive 8,9-epoxide, which can 
form adducts with DNA and protein, and thereby results in DNA damage. 
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Recently, several method have been developed to measure individual levels of exposure 
to aflatoxins. The information provides data on risk posed due to aflatoxins. It has been 
demonstrated that AFB1 binds covalently to albumin. AFB1-lysine has been identified as 
a major adduct in rat albumin. It has also been observed in human sera (Wild et al., 1986; 
Sabbioni et al., 1987; Wild et al., 1990; Anitha et al., 2011). In experimental animals, the 
level of albumin adduct reflects the degree of DNA damage in the liver (Turner et al., 
1998). Thus, AFB1-lys acts as biomarker for assesses sent of human exposure to 
aflatoxins.  
 
 Aflatoxin albumin adducts are found in peripheral blood after exposure to aflatoxin 
B1.  The measurement of these adducts is a potentially useful tool in the epidemiological 
studies of the role of AFB1 in the etiology of liver cancer. Three complementary 
approaches to the quantitation of AFB1-albumin adducts are described: (a) Enzyme 
linked Immunosorbent assay (ELISA) performed directly on intact albumin  (direct 
ELISA); (b) ELISA performed on an albumin hydrolysate (hydrolysis ELISA); (c) high 
performance liquid chromatography (HPLC) fluorescent detection of AFB-lys adduct 
after albumin hydrolysis and immunoaffinity purification. These techniques have been 
validated by direct comparison with rat albumin samples modified to a known extent 
(reference). Detection limits of 100, 50 and 5 pg, aflatoxin per mg human albumin were 
determined for the three methods respectively (Turner et al., 1998). Samples obtained 
from individuals from Thailand, the Gambia, Kenya, and France have been used to 
validate the measurement of AF-albumin adducts by these three methods (Turner et al., 
1998). Levels of 5 to 1064 pg aflatoxin-albumin adduct mg-1 of albumin were observed in 
the former two countries while no adducts were detected in samples from France (Turner 
et al., 1998). The relative properties of the three assays, with special regard to their 
application in epidemiological studies, are considered to detect aflatoxin in human (Wild 
et al., 1990). A combination of the hydrolysis ELISA for large scale screening followed 
by confirmatory analysis in positive samples by HPLC is suggested as an optimum 
methodology (Wlid et al., 1990; Anitha et al., 2011).    
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 ELISA was used in earlier studies to determine human exposure to aflatoxin at an 
individual level and consequently allows a better assessment of the role of aflatoxin and 
its interaction with hepatitis B virus infection, in the aetiology of liver cancer. 
Measurements of aflatoxin bound to serum albumin in children and adults from various 
African countries shows that between 12 and 100 % contain aflatoxin-albumin adducts, 
with levels up to 350 pg AFB1-lysine equivalent/mg albumin. In Thailand, lower levels 
and prevalence of this adduct were observed, while no positive sera were detected from 
France or Poland (Wild et al., 1990). The study in 250 samples in India showed aflatoxin-
albumin adducts level ranged from 2.5 to 75 pg mg-1 albumin (Anitha et al., 2011). 
 
 Studies on AFB1 exposure in the United Kingdom population were done by 
measuring levels of serum AFB1-albumin, using ELISA and high-performance liquid 
chromatography with fluorescence detection. Serum albumin was extracted, and AFB1-
lysine, the digest product of AFB1-alb, was isolated and measured. A good correlation 
was found between calibration of ELISA results and HPLC (r=0.972; p<0.001). ELISA 
was subsequently used to analyze human serum albumin (Turner et al., 1998). Thus this 
study demonstrated that ELISA is sensitive in detection of AFB1-lys biomarkers and 
results are comparable to HPCL studies.  
 
             Therefore, to assess the level of aflatoxin exposure among populations in India, 
this study was undertaken to standardize the methods for the detection of aflatoxin 
biomarker by ELISA using antibodies produced at ICRISAT and it is validated (Anitha et 
al., 2011) with HPLC as described by (Sabbioni, 1990).  
  
 Earlier, AFB1-lysine and AFB1-ovalbumin adducts were prepared in vitro using 
AFB1-dibromide (Sabbioni et al., 1987; Chapot and Wild, 1991). This was a tedious 
method to prepare adduct and was time consuming. In this study, AFB1-lysine and 
AFB1-ovalbumin was prepared by oxidizing the AFB1 to AFB1-8,9 epoxide by the 
chemical oxidant MCPBA. Long incubation periods of up to 6 h can form more epoxide 
when compare to short incubation period. The epoxide was then conjugated with N-α-
acetyl lysine or ovalbumin through overnight incubation. Since the ovalbumin does not 
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dissolve completely, longer incubation time with gentle shaking may permit the 
formation of more conjugate.  
 
The spectral reading of AFB1-lysine gave two peaks at 275 nm and 340 nm. In 
the study of Sabbioni (1990) AFB1-lys peaks were at 275 nm and 335 nm. In this study, 
the peaks are near enough (275nm and 340nm). But the difference between absorption 
value between 335 nm and 340 nm was found to be only 0.1 OD. The adduct was 
aliquoted and stored at –20˚C. It was stable for over a year. Sabioni and Sepai (1998) 
found that the adduct can be stored over a year as solid or in solution at pH 7.4 to 8.0 at   
–50˚C. In present study, when adduct was stored at 4˚C in liquid form. There was a 20% 
loss within two months.  
 
Albumin prepared from the serum by the protocol detailed in section 3.3.4 gave 
high yield and purity. The yield was Approximately 12 mg 500 µl-1 of the albumin when  
saturated ammonium sulphate (4.1M), which has neutral pH, was used. Wild et al., 
(1990b) got approximately 10 mg 500 µl-1 .  It was about 50% of the theoretical yield. For 
ELISA, less than 2 mg was deemed to be sufficient.  
 
Since AFB1 is a small molecule, it does not elicit good immune response in 
animals. Therefore, it is conjugated to a hapten or carrier protein (Waliyar et al., 2005a). 
Usually BSA is used as carrier protein for immunizing rabbits (for polyclonal antibodies 
or mice, for monoclonal antibodies). Since in human and animals, AFB1 occur as an 
epoxide, the AFB1 molecules are first modified to epoxide using chemical oxidation. 
This is linked with BSA and used for immunization. Similar protocol was used in this 
study to produce antibodies to AFB1 epoxide (Srinivas, 2003). These antibodies were 
then utilized in this study to detect AFB1-lys in human serum. It was validated using 
HPLC (Anitha et al., 2011). Since antibodies produced against AFB1 epoxide may cross 
react with pure AFB1, comparative studies were done using antisera to AFB1 and AFB1 
epoxide. This showed that antibodies produced to AFB1 epoxide can cross react with 
AFB1, but antibodies to AFB1 did not react with the epoxide form. To eliminate any 
cross reaction with albumin, antibodies were adsorbed with human serum albumin prior 
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to use in ELISA. Further, serum albumin from healthy controls was used in AFB1-lys 
standards to minimize the cross reaction affect on the final data, which are deduced from 
the standard graph plotted from AFB1-lys standards. Wild et al. (1990) used human 
serum albumin from healthy controls supplied by Sigma. 
  
The detection limit of AFB1-lysine for the ICRISAT antisera was found to be 7.8 
pg ml-1 to 2 ng ml-1 (Anitha et al., 2011). Turner et al. (1998) used 7.13 pg ml-1 to 1.83 ng 
ml-1 for  ELISA.  
 
Monoclonal antibody 
The monoclonal antibody that was produced against AFB1-KLH is highly specific to 
AFB1-albumin. Since the conjugate is produced by epoxidation process it can identify 
any AFB1-epoxide conjugates. However, the monoclonal antibody had a detection limit 
of 4 ng per ml-1. Whereas, the polyclonal antibody had a detection limit of 7.8 pg ml-1. 
Hence, the polyclonal antibodies were considered more suitable for the detection of 
afaltoxin-albumin adduct in human blood. 
 
Sample processing  
Albumin hydrolysis was carried out with proteinase K. Proteinase K digestion results in 
breakdown of proteins into individual amino acids and oligomers of short size. Therefore, 
albumin digested with proteinase K was recommended for purification through columns 
to remove undigested albumin and large sized peptide. But, in this study we found that 
albumin hydrolyzed with proteinase K for longer time (17 h and more) did not contribute 
any background and thus the column clean up of the sample was eliminated further 
simplifying the procedure. This reflected in 96±11% recovery of the AFB1-lysine in 
artificially spiked samples, suggesting that there was not much loss during digestion with 
proteinase K.  
 
In this study, HBV positive samples and healthy control were used to validate the 
protocol for standardization of assessment of AFB1-lys in serum. Of 673 samples, 86 
samples tested positive to AFB1-lys, indicating exposure to aflatoxins. In these 86 
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samples which showed aflatoxin contamination, the aflatoxinB1-albumin content ranged 
from 2.5-677 pg mg-1 (mean adduct level is 181.9 ±5 and SD 1.49 ± 7.). With the 
standardized protocol, large numbers of samples could be analyzed to determine aflatoxin 
exposure in humans.   
 
At 5% level of significance p value 0.039 (<0.05) indicates presence of aflatoxinB1-
lysine adducts and hepatitis B has synergistic effect on liver damage. The hypothesis of 
current experiment is aflatoxin B1 and hepatitis B together aggravates the liver damage. 
When liver is exposed to Hepatitis B virus the hepatocytes get cell injury and undergo 
structural changes (chapot and wild 1991). At the same time the entry of aflatoxin into 
the hepatocyte increase the degree of liver cell damage. The aflatoxins which get 
accumulated in liver cells will bind with plasma protein albumin which is basically 
produced from liver cells.  Apart from this when the hepatocytes multiply during repair 
process the aflatoxins bind to DNA and leads to mutation. The result in this study also 
shows that the presence of hepatitis B activates aflatoxin B1 which then together 
damages the liver cells rather than aflatoxin B1 alone or Hepatitis B alone. These results 
are similar to that of Kew, 2003. 
 
In a previous Indian study Murugavel et al (2007)using immunoperoxidase test, 
reported association of AFB1 deposits in 58% of 32 human liver biopsies samples from 
HCC cases, 15 of which were positive to HBV. However, in the same study ELISA assay 
for AFB1 biomarker was reported negative. A reason for this disparity is unclear. 
However, it is speculated that this may be linked to time of assessment, as AFB1-lys 
biomarker is detectable for up to 2 months from the first exposure to aflatoxin. 
Nonetheless, Murugavel et al., demonstrated significant association of AFB1 toxicity with 
HCC cases in India, and emphasize the need for wider surveillance to determine AFB1 
exposed populations in India.  
 
The IC-ELISA developed in this study could be a potential tool for such 
epidemiological studies to identify vulnerable groups. This test is simple to perform, cost-
effective and enables high-throughput analysis. After thorough validation, IC-ELISA has 
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the potential to serve as a rapid tool to identify AFB1 exposed individuals. Vulnerable 
cases can be subjected to further specific tests to assess HCC risk, institute remedial 
treatments and implement appropriate strategies to minimize aflatoxin contamination in 
diets of communities at high risk of AFB1 exposure.  
 
Aflatoxins together with chronic hepatitis B virus (HBV) infection contribute to the 
high incidence of hepatocellular carcinoma in developing countries (Williams et al., 
2004). An understanding of the mechanism of interaction between these two factors 
could provide a strong rationale for developing effective prevention strategies. A study in 
the Gambia, the effect of environmental factors (place of residence and timing of sample 
collection) and host factors (age, sex, HBV status and inter-individual variations in 
carcinogen metabolizing enzymes) in determining blood-aflatoxin adduct levels in 357 
individuals, of whom 181 were chronic HBV carriers, emphasizes the priority to reduce 
aflatoxin exposure in these communities by primary prevention measures (Wild et al., 
2000).  
 
Usually, people avoid moldy foods and humans are usually an aflatoxin tolerant 
species. However, in times of food scarcity, or under conditions of poverty, people 
usually have no option but to use lower-priced, poor quality food, which is commonly 
contaminated (Williams et al., 2004). Post harvest measures to restrict aflatoxin 
contamination of groundnut crops were shown to reduce exposure in West African 
villages (Turner et al., 2005).  
 
p53 Mutation 
One study in Taiwan found that, in the presence of aflatoxin, the p53 249ser mutation 
was significantly more frequent among HBV positive than negative subjects (Montesano 
et al., 1997) another study in Qidong shows the p53 249 mutation is frequent in cirrhosis 
patients that control patients (Xing-Hua et al., 2003). In the present study 238 samples 
were analysed for p53 mutation. Among this 130 samples were Hepatitis B positive and 
108 samples were control. We found 29 samples were positive for aflatoxin-albumin 
adduct and hepatitis B. Among these, 29 aflatoxin-albumin positive samples, 8 samples 
 119
are both Hepatitis B positive and p53 mutation positive (p=0.07). At 10% level of 
significance, if probability <0.1, then, presence of aflatoxin-albumin adduct and p53 
mutation are dependent, otherwise, independent. Here, we found that presence of 
afaltoxin and p53 mutation is dependent in Hepatitis B positive samples. Further 
epidemiological studies of the interrelationship among aflatoxin exposure, HBV status, 
and the presence of the p53 249ser mutation could help clarify whether HBV acts as a 
confounder or as a synergistic partner with aflatoxin. 
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7. SUMMARY AND CONCLUSION 
 
Aflatoxins are the fungal secondary metabolites produced by Aspergillus flavus and 
related species. Aflatoxins are difuranocoumarin compounds, which include aflatoxin B1, 
B2, G1, G2, M1, M2 and other derivatives. The International Agency for Research on 
Cancer (IARC) recognizes aflatoxin B1 (AFB1) as a liver carcinogen. Aflatoxin exposure 
in humans and animals results from the consumption of contaminated food. Studies on 
humans implicated AFB1 in several illnesses, most notably liver cancer and growth 
retardation in children. Synergism was demonstrated between Hepatitis B and C virus 
infections and hepatocellular carcinoma when fed with aflatoxin contaminated food.  
 
Significant advances have recently been made in the development of methods to 
measure individual levels of exposure to aflatoxin. AFB1 covalently binds to serum 
albumin, especially to the amino acid lysine. AFB1-lysine has been identified as a useful 
quantifiable biomarker in human serum to determine the exposure to aflatoxin B1. In 
experimental animals, the levels of AFB1-albumin adduct reflects the degree of DNA 
damage to the liver, the target organ for cancer. The measurement of aflatoxin in humans 
was shown to provide vital information on the role of AFB1 in the etiology of liver 
cancer in human and all other diseases including Hepatitis B, Hepatitis C and cirrhosis of 
liver. This information can further be used to assess the aflatoxin exposure risk among 
various sections of human populations to implement appropriate intervention measures to 
minimize the risk of aflatoxin exposure related illnesses. Various serological-based 
assays [enzyme linked-immunosorbent assays (ELISA) using antibodies] have been 
developed to determine the levels of aflatoxin adducts in humans. These were based on 
measuring AFB1-lys adduct in serum.  
 
The IC-ELISA developed in this study could be a potential tool for epidemiological 
studies to identify vulnerable groups. This test is simple to perform, cost-effective and 
enables high-throughput analysis.  
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This study also involved the development and standardization of a method for 
detection of aflatoxin in human serum. Thus, monoclonal and polyclonal antibodies were 
produced. It was observed that polyclonal antibodies had high detection limit. These were 
used to evolve an indirect competitive ELISA method.  This is a simple assay that can be 
applied in field studies to a relatively large number of samples. The protocol to prepare 
the AFB1-lys and AFB1-oval adduct was standardized in vitro by forming AFB1-8,9 
epoxide, and the epoxide was conjugated with lysine or ovalbumin. These were used at 
various concentrations to standardize the ELISA procedure using antibodies produced 
indigenously. Method for the extraction of albumin from serum fraction was 
standardized. After albumin hydrolysis with proteinase K, the AFB1-lysine adduct 
concentration was estimated by ELISA. The detectable limit of AFB1-lys in blood using 
polyclonal antibody through ELISA was found to be 7.8 pg per 100 µl. The assay has 
96±11% recovery of AFB1-lysine adduct in artificially spiked samples. This assay was 
validated by testing 673 hepatitis B virus positive and cirrhosis of liver patient samples 
and healthy control samples for the AFB1 exposure. Eighty six of them tested positive for 
aflatoxin-lysine adduct. Out of this seventeen samples were from healthy control and 
sixty nine samples were from hepatitis B and cirrhosis of liver positive samples.  
 
The Restriction fragment length polymorphism (RFLP) method was standardized 
to detect aflatoxin induced p53 mutation. Two hundred and thirty eight hepatitis B 
positive patient samples and healthy control samples were analyzed for the presence of 
p53 mutation. of these 10 samples were found to have mutation. There was synergistic 
effect between aflatoxin presence and p53 mutation in Hepatitis B positive samples.  The 
method standardized in this study would be useful for further studies on screening large 
number of samples from various sections of populations in India to assess the level of 
aflatoxin exposure.  
 
In conclusion,  
• This study has simplified the preparation of AFB1-ova and AFB1-lys standards 
that are necessary to use as standards in ELISA assay to determine the aflatoxin 
concentration in human serum 
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• Standardized a simple protocol for the preparation of serum samples for aflatoxin 
analysis 
• Produced monoclonal and polyclonal antibodies and standardized IC-ELISA to 
detect aflatoxin-albumin adduct in human blood 
• Validated the antibodies produced during this period for its efficacy and 
sensitivity, and showed that it is high in titer 
• Evaluated 380 hepatitis B virus positive samples and detected 70 samples as 
positive to aflatoxins. Out of 293 control samples 16 samples are positive to 
aflatoxins. 
 
Further studies should focus on screening more number of hepatitis B virus positive 
samples and random population to assess the likely risk of such patients for liver cancer 
and to suggest appropriate remedial measures through dietary interventions to minimize 
the risk of liver cancer. Wider analysis by testing various groups of populations from 
different socio-economic backgrounds and agro-eco regions is necessary to asses the risk 
of aflatoxin exposure among Indian populations to develop appropriate intervention 
strategies.  
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8. Appendix 
 
 8.1. Buffers and reagents for ELISA (Kumar et al., 2004) 
 
8.1.1. Coating buffer (Carbonate buffer, pH 9.6) 
Na2CO3  - 1.59 g 
NaHCO3  - 2.93 g 
Distilled water - 1000 ml 
8.1.2. Phosphate buffer saline (PBS), pH 7.4 
      Na2HPO4 2.38 g 
      KH2 PO4 0.4 g 
      KCl 0.4 g 
      NaCl 16.0 g 
      Distilled water to 2 l 
No need to adjust the pH 
8.1.3. Phosphate buffer saline Tween (PBS-T) 
      PBS 1 l 
      Tween-20 0.5 ml 
8.1.4. Substrate buffer (diethanolamine buffer) for ALP system 
10% Diethanolamine 
Prepare 10% diethanolamine in distilled water and store at 4˚C. Adjust pH to 9.8 with 
con.HCl. Prepare 0.5 mg/ml p-nitro phenyl phosphate (PNPP) in 10% diethanolamine, 
pH 9.8 (for each 15 mg table 30 ml substrate buffer is required). This solution should be 
prepared fresh. Don’t store left over buffer. 
Note: Diethanolamine is toxic and harmful to eyes. Take necessary care to avoid contact 
with skin. PNPP convert to p-nitrophenol after reacting with APL. Plates after adding 
substrate must be handled extremely carefully.  
 135
8.2. Buffer for the preparation of aflatoxin adducts and for extraction of albumin 
 
8.2.1. 0.01 M phosphate buffer (pH 7.2) 
   
K2HPO4 
KH2PO4 
 
8.2.2. Preparation of saturated ammonium sulphate (4.1 M at 25 oC). 
 
Add 761 g of ammonium sulphate to 1L of distilled water and adjust the pH to 7.0. 
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8.3. Reagents and buffers for Polyacrylamide Gel Electrophoresis (PAGE) 
 
8.3.1. Stack gel buffer (1 M Tris-HCl, pH 6.8) 
Tris base 12.1 g 
Dissolve in 70 ml distilled water, adjust pH to 6.8 with 1 N HCl and make up to 100 ml 
with distilled water. 
 
8.3.2. Resolving gel buffer (1 M Tris-HCl, pH 8.8) 
Tris base 12.1 g 
Dissolve in 70 ml distilled water, adjust pH to 8.8 with 1 N HCl and make up to 100 ml 
with distilled water. 
 
8.3.3. *Acrylamide/Bis (30:0.8 w/w) mixture 
Acrylamide 30 g 
Bis acrylamide 0.8 g 
Distilled water to 100 ml 
Store this solution at 4 0C in amber coloured bottle or wrap the bottle with aluminum foil 
to avoid exposure to light. 
 
*Precaution: Acrylamide is a neurotoxin. Direct contact with skin or inhalation of 
acrylamide should be avoided. Prepare this solution in fume hood and always wear 
gloves. 
 
8.3.4. 10% ammonium persulphate (APS) 
APS 100 mg 
Distilled water 1 ml 
Note: Always prepared fresh solution before use. 
 
8.3.5. TEMED (Sigma, Cat.# T9281) 
Store at 4 oC. 
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8.3.6. Electrode (running or tank) buffer, pH 8.3 
Tris base (25mM) 3 g 
Glycine (250 mM) 14.4 g 
SDS (1%) 1 g (add this into buffer, for separating proteins) 
Distilled water to 1 litre. No need to adjust pH. Store at room temperature. 
 
8.3.7. Plug gel composition (optional) 
Note: Plug gel was used to seal the bottom of the gel mould. Use of this depends on the 
type of electrophoresis unit. 
Acrylamide: Bis mixture 1.75 ml 
Resolving gel buffer 1 ml 
Distilled water 1 ml 
TEMED 20 µl 
10% APS 40 µl 
or 2% agarose prepared in running buffer 
 
8.3.8. Resolving gel composition (12%) 
Acrylamide: Bis mixture           12 ml            
Resolving gel buffer                 11.25 ml       
Distilled water                          7 ml              
10% SDS                                  300 µl           
TEMED                                      20 µl              
10% APS                                  100 µl            
 
8.3.9. Stacking gel composition (4%) 
Acrylamide: Bis mixture  1.5 ml 
Stacking gel buffer   1.25 ml 
Distilled water   7 ml 
10% SDS    100 µl  
TEMED    15 µl 
10% APS    200 µl 
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8.3.10. Lamelli buffer 
Distilled water    4.57 ml 
1 M Tris-HCl buffer pH 6.8  0.63 ml 
40% Glycerol    2.5 ml 
10% SDS    2 ml 
2-mercaptoethanol   0.1 ml 
0.5% Bromophenol blue  0.2 ml 
 
Note: Mix acrylamide:bis solution, gel buffer, distilled water and TEMED mix well, then 
add APS, swirl the flask and immediately pour into the gel mould. 
Caution: Unpolymerized acrylamide is a neurotoxin. Gloves should be worn when 
preparing this solution. 
Procedure 
1. Assemble the vertical slab gel apparatus in casting mode as per the manufacturer 
instructions. 
2. Pipette 1 ml of the plug gel solution into the gel mould from a corner and allow it to 
set. Note: Some units may not require sealing the bottom with a plug gel. 
3. Pour resolving gel solution into the gel mould leaving about 3 cm space for stacking 
gel. Gently overlay with water. A sharp water-gel interface will be visible with the 
polymerization of the gel. Note: Add 10% SDS as shown in table, if gel is meant for 
separating proteins. 
4. Decant the water overlay by gently tilting the gel mould. 
5. Pour stacking gel solution into the gel mould and insert a comb and allow the gel to 
set. 
Care must be taken not to trap air bubbles below the comb’s teeth. Note: Add 10% SDS 
as shown in table if gel is meant for separating proteins. 
6. Carefully lift the comb straight-up, without disturbing the wells. Wash the wells with 
water to remove unpolymerised acrylamide. 
7. Fill the lower tank of the electrophoresis unit with electrode buffer. Note: Add SDS 
into electrode buffer, if gel is meant for separating proteins. 
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8. Insert the gel mould into the electrophoresis unit making sure not to trap air bubbles 
under the gel. 
9. Fill the upper tank with electrode buffer. Avoid direct pouring of buffer into the wells. 
10. Load the protein samples for separating in the gels. 
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8.4. Reagents for silver staining of proteins 
 
8.4.1. Fixing solution (Prepared freshly before use) 
Glacial acetic acid 3 ml 
Methanol 50 ml 
distilled H2O 147 ml 
 
8.4.2. DTT wash solution (0.05% Dithiothreitol (DTT) 
DTT 5 mg 
Distilled H2O 10 ml 
This can be stored as aliquots at  -20 oC. Note: Diluted this to 1:100 freshly before use. 
 
8.4.3. Silver nitrate solution (Prepared freshly before use) 
Silver nitrate 400 mg 
distilled H2O 200 ml 
 
8.4.4. Developer solution (Prepare freshly before use) 
Na2CO3 6 g 
Formaldehyde 100 µl 
Distilled H2O 200 ml 
 
8.4.5. Stop solution 
Glacial acetic acid 1 ml 
Distilled H2O 99 ml 
 
Staining procedure (all steps performed at room temperature) 
1. Gel was placed in a fixing solution for 30 min, with gentle shaking.  
2. Gel was rinsed with in distilled H2O for 3 times, 10 min given for each wash.  
3. Then 100 ml of DTT solution was added and kept for shaking for 30 min. 
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4. Gel was rinsed with distilled H2O, and placed it in silver nitrate solution for 30 
min. Then gel was rinsed quickly with distilled water and placed in developer till 
bands are clear. Reaction was stopped by adding stopper solution for 20 min.  
5. The stopper solution was then replaced it with distilled water. 
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8.5. Agarose gel electrophoresis 
Agarose gels are prepared by melting agarose in the desired buffer until a clear 
transparent solution is obtained. The molten agarose solution is poured into a mould 
(boat) and allowed to harden. Upon hardening the agarose forms a matrix, the density of 
which depends on the concentration of the agarose. 
8.5.1. Materials 
• Horizontal electrophoresis unit 
• Power supply 
• Agarose (electrophoresis grade; BioRad, Cat.# 162-0125) 
• UV Transilluminator (302 nm wave length) 
 8.5.2. 10x Electrophoresis buffer (TBE buffer, pH 8.3) 
Tris base (0.45 M) 54 g 
Boric acid (0.45 M) 27.5 g 
0.5 M EDTA, pH 8 (0.01 M) 20 ml 
Distilled water to 1 liter 
It is not necessary to adjust pH. Sterilize by autoclaving and store at room temperature. 
8.5.3. Working solution ( 0.5x ) 
To 5 ml of 10x TBE buffer add 95 ml of sterile distilled water. The final concentration of 
Tris-base, boric acid and EDTA in working solution is 0.045 M, 0.045 M and 0.001 M, 
respectively. 
8.5.4. 5x Sample buffer (Gel loading buffer) 
Bromophenol blue (0.25%) 5 mg 
Xylene cyanol FF (0.25%) 5 mg 
Glycerol (30%) 3 ml 
Sterile distilled water to 10 ml 
8.5.5. 1% Ethidium bromide solution 
Ethidium bromide 100 mg 
Distilled water 10 ml 
Store in a dark coloured bottle at 4 0C. 
8.5.6. Working solution (0.5 µg/ml): To 100 ml water or molten agarose, add 5 µl of 1% 
ethidium bromide. 
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Caution: Ethidium bromide is a carcinogen. Gloves should be worn when handling and 
care must be taken to dispose materials containing this substance. 
8.5.7. Procedure 
1. Prepare agarose at the desired concentration (w/v) in 1x TBE buffer (for 2% gel, 
dissolve 2 g agarose in 100 ml buffer) and boil in a microwave oven or on a hot water 
bath, with intermittent shaking until all the agarose is completely dissolved. Replace 
evaporation loss with distilled water. Note: Ethidium bromide can be directly added into 
molten agarose [8 µl (0.05µg/ml) /100ml]. This is kind of staining is used for routine 
analysis. However, if the gel is for estimating molecular size of DNA fragments, do not 
add ethidium bromide into the gel. It affects DNA migration in gel. 
2. Seal the edges of the gel tray with a tape and place the comb at one end of the tray 
surface. 
3. Cool the agarose solution to about 50 0C and pour into the gel tray to a thickness of 4-
5 mm and allow the gel to set. Note: It will take about 20 min for agarose to harden. 
4. Remove the tape and place the gel tray in the electrophoresis unit and fill the unit with 
0.5x TBE buffer so that there is 2-3 mm of buffer over the gel surface. Then remove the 
comb carefully. Note: Wells should be towards cathode end (black colour leads). The 
migration of DNA will be towards anode (red colour leads) 
5. Mix 6 µl of loading buffer to 30 µl of PCR product and load slowly into the wells. 
Avoid overloading of the wells. 
6. Load DNA molecular weight marker. 
7. Connect electrophoresis unit to the power pack and turn on power supply until the 
bromophenol blue dye reaches the bottom of the gel. (Approximately 60 min at 100 V, 
for DNA to migrate 7 cm from the wells in a 1% gel) 
8. Remove the gel from the tray and stain in ethidium bromide solution (0.5 µg/ml) in 
water for 15 min with gentle agitation. Then destain by soaking the gel in water for 5 
min. 
9. Observe the gel under UV Transilluminator using UV protective goggles or a full 
safety mask that efficiently blocks UV light. Photograph the gel using an orange filter 
fitted camera. Caution: UV radiation is very dangerous to the skin and particularly to the 
eyes. It is absolutely essential to use UV-protective goggles. 
 144
8.6. Definitions of some terms 
(Coleman et al., 1992) 
 
Term Definition 
Phagocytic activity Ingestion of cells or particles (antigen) by phagocytes or 
the process by which phagocytes engulf the other cells. 
Lymphocyte Mononuclear cell, approximately 7-12 µm in diameter, 
containing a large, round nucleus with densely packed 
chromatin and a small thin outer layer of cytoplasm. 
Several classes of lymphocytes are identified on the 
basis of surface antigens that they express and their 
roles in immune responses. 
CD4 Diagnostic surface antigen of TH and TD cells. This 
antigen is associated with the T cell antigen recognition 
receptor and contributes to class II MHC restriction of 
these cells. 
CD8 Diagnostic surface antigen of Tc and Ts cells. This 
antigen is associated with the T cell antigen recognition 
receptor and contributes to class I MHC restriction of 
these cells. 
Mutagenic The agent which can cause mutation 
Immunosuppressor The agent which can suppress the immune system 
Hepatocarcinogen The agent which is responsible for liver cancer 
Hepatotoxin Substances toxic to liver  
Degranulation Process whereby granulocytes discharge the contents of 
their cytoplasmic granules (lysosomes or specific 
granules). This occurs during the formation of 
phagolysosomes by neutrophils or in the discharge of 
specific granule content of basophils and mast cells. 
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THE STUDY ON SERUM AFLATOXIN LEVELS IN LIVER 
DISORDERS ASSOCIATED WITH INCREASED RISK OF 
HEPATOCELLULAR CARCINOMA 
 
 
Informed Consent for participating in the study by providing blood sample 
for estimation of serum aflatoxin levels. 
 
 
 
        Date ……….  
 
I ………………………..S/o, D/o ……………………hereby agree to 
participate on the above mentioned study and agree to provide blood sample 
for estimating serum Aflatoxin levels. I have been explained in detail the 
nature of the study – 
 
1) The aim of the study is to estimate aflatoxin levels in different liver 
diseases and compare with those who do not have liver disease. 
2) The outcome of the study may prove beneficial in taking some 
preventing measures. 
3) I have been assured of confidentiality.  
4) I have been given opportunity at my free will to ask questions and 
seek clarifications. 
 
 
 
 
Signature of the Investigator           Signature of the Patient/Representative 
                  Or     authorized by the patient. 
Person authorized by Investigator   
 
 
Signature of the independent witness           
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CASE RECORD FORM 
 
Name       Serial No. 
Age    Sex   Address     
PR No.    IP No.        
DOB      
D/o Admission     
D/o Discharge      
Final Diagnosis     Tel:  (Landline) :  
Mobile : 
Co-Morbid Conditions 
Diabetes Type  Duration Medication:  OHA
 
    Insulin 
 
 
 
     
 
 
 
    Both
 
  Diet Control 
 
 
Hypertension   Duration Medication ____________________________ 
                            
 
 
CAD   No Yes    
 
COPD/Asthma  No Yes 
 
Lifestyle     
Physical Activity  Sedentary 
 
   Moderate activity  
 
 Heavy activity
 
 
 
Smoking   No  
 
 Yes   
 
         Packs/day
 
 
 
Alcohol   Whiskey    
 
  Wine 
 
    Beer 
  Local 
 
 
  
   Quantity ______ml  No. of years 
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PROTOCOL ON SERUM AFLATOXIN LEVELS IN LIVER DISORDERS ASSOCIATED WITH 
INCREASED RISK OF HEPATOCELLULAR CARCINOMA 
 
Name       Serial No. 
Age    Sex   Address     
PR No.    IP No.        
DOB      
D/o Admission     
D/o Discharge      
Final Diagnosis      Tel:  (Landline)  
Mobile 
Food Frequency Questionnaire 
 
1. Do you consume the following foods?  
a. Peanuts     Yes   No 
b. Corn    Yes   No 
c. Wheat    Yes   No 
d. Rice    Yes   No 
e. Barley    Yes   No 
f. Soyabeans   Yes   No 
g. Raw milk (unpasturized)  Yes   No 
h. Red Chillies   Yes   No 
 
2. How frequently do you consume these foods? 
a. Peanuts Daily Alternate days        Weekly once  Rare 
b. Corn  Daily Alternate days  Weekly once  Rare 
c. Wheat  Daily Alternate days  Weekly once  Rare 
d. Rice  Daily Alternate days  Weekly once  Rare 
e. Barley  Daily Alternate days  Weekly once  Rare 
f. Soyabeans  Daily Alternate days  Weekly once  Rare 
g. Raw milk Daily Alternate days  Weekly once   Rare 
h. Red Chillies Daily Alternate days  Weekly once   Rare 
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3. Cooking practices 
a. In what cooked form do you consume peanuts? 
Boiled  Roasted Chutneys Peanut butter Any other_____  
b. In what cooked form do you consume corn? 
Boiled  Roasted Corn flakes Any other__________________ 
c. In what cooked form do you consume wheat and its products? 
Boiled  Roasted Baked  Fried  Any other_____ 
d. In what cooked form do you consume rice? 
Boiled  Roasted Fried  Any other__________________ 
e. In what cooked form do you consume barley? 
Boiled  Roasted Barley water Malted beverages Any other___ 
f. In what cooked form do you consume soyabeans? 
Boiled  Roasted Baked  Any other__________________ 
4. Quantity of foods consumed 
 Consumption 
Gm/kg per month 
No. of person in 
family 
 
Peanuts    
Corn    
Wheat    
Rice    
Barley    
Soyabeans    
Milk (1 cup = 200ml)    
Red Chillies    
5. Source   Supermarket  Kirana shop  Self produced & stored 
   Govt. fair price shop Others (specify) _____________ 
6. Socioeconomic profile 
Employment   Government  Non Govt.  Self  
 Salary (per month) 
Education   illiterate   Metric   Graduate  
  House    Own   Rental    Company  
Daily transport  4 Wheeler  2 Wheeler  Public transport 
Visits – Abroad  None   1-2   >4 
Admitted in ward – 
 Free general ward  Paying general ward  Non AC  
 AC  
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Fasting glucose:       
 
   Height:      Hip Circum:  
Triglycerides:           
 
   Weight: 
 
     Wt / H :      
 
     
Total cholesterol:     
 
   BMI :     
 
 
Blood pressure:        
 
   Waist Circum: 
 
 
        
Kal  
 
 
 
 
 
 
 
 
 
Symptom Profile 
Symptom Date Symptom Date 
First Symptom  
Elaborate 
 Distension of 
Abdomen  
 
Hematemesis/ Malena  Febrile illness  
Edema of feet  Encephalopathy  
Jaundice    
Others    
 
Signs Profile 
Jaundice   Ascites  
Pruritic marks  Edema feet  
Hepatomegaly  Lymph nodes  
Splenomegaly  Mass  
Others    
 
Metabolic Syndrome Profile 
MELD :   MADDREYS:                     {4.6 x [PT(P)-PT(C)] + 
Total Bil} 
 
 
 
Aetiology Profile 
Hepatitis B:         
 
 Hepatitis C: 
 
  Alcoholism:         
 
 
 
Autoimmune:      
 
 Wilson:        
 
  Cryptogenic:         
 
 
 
NAFLD related:  
 
 Other:           
 
  Hepatocellular Ca: 
 
 
Date          S.Bilirubin                 PT (P)              PT (C)        P-C                 INR              Creatinine 
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 MELD SCORE                         MELD 
10{0.957Lg(Scr)+0.378Lg(Tbil)+1.12Lg(INR)+0.643} 
 
 1 Point 2 Points 3 Points Patients points 
Bilirubin (mg/dl) <2 2-3 >3  
Albumin (mg/dl) <3.5 2.8-3.5 <2.8  
INR <1.7 1.7-2.3 >2.3  
Ascites None Slight or controlled 
medically 
Moderate or 
severe 
 
Encephalopathy None Stage 1-2 Stage 3-4  
Class A = 5-6 points, B = 7-9 points, C= 10-15 points 
Other Investigation Profile   CPT score   
 
 
 
 
 
 
 
 
Sero Molecular Profile 
 
 
 
 
 
 
 
 
Biochemistry Profile  (ULN) 
S.Bilirubin.T:      
 
 (        ) Total protein:         
 
   
S.Bilirubin.D:      
 
 (        )          Alb:                          
 
 
ALT (SGPT):     
 
   (        )     Glob:                        
 
   
AST (SGOT):     
 
 (        )       Urea:                        
 
  (        ) 
Alk.phosph:       
 
 (        )       Creatinine:              
 
  (        ) 
GGT:          
 
 (        ) Uric Acid:             
 
  (        ) 
 
BIOPSY PROFILE 
 
 
UGI Endoscopy:                Hb:            
 
 
US Abdomen:                    TLC:         
 
 
CT ABD / MRI:                     DLC:         
 
 
X-ray chest:                        Platelets:    
 
 
HBsAg:                    
 
  Anti-HCV:             HIV:     
 
  
HBeAg:                    
 
  HCV Genotype:   
 
  Others    
 
 
Anti-HBe:          
 
  HCV Quant :        
 
 
HBV Genotype:        
 
  HBV Quant:         
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Chart 1: Aflatoxin-lysine positive status in Hepatitis B positive and control samples 
S.No Patient 
ID 
Age Gender Diagnosis Aflatoxin 
B1-lysine 
status 
AFB1 concentration in 
pg/mg of albumin 
1 AFB01 45 M HBV Positive 31.5 
2 AFB02 43 M HBV Negative 0 
3 AFB03 47 M HBV Negative 0 
4 AFB04 56 M HBV Positive 129 
5 AFB05 52 F HBV Negative 0 
6 AFB06 61 M HBV Negative 0 
7 AFB07 45 M HBV Positive 111 
8 AFB08 47 F HBV Negative 0 
9 AFB09 49 M HBV Negative 0 
10 AFB10 58 M HBV Positive 676.5 
11 AFB11 49 M HBV Negative 0 
12 AFB12 53 M HBV Negative 0 
13 AFB13 56 M HBV Negative 0 
14 AFB14 48 F HBV Negative 0 
15 AFB15 41 M HBV Negative 0 
16 AFB16 58 F HBV Negative 0 
17 AFB17 48 M HBV Positive 403.9 
18 AFB18 56 F HBV Negative 0 
19 AFB19 50 M HBV Positive 180.8 
20 AFB20 40 F HBV Negative 0 
21 AFB21 49 M HBV Negative 0 
22 AFB22 61 F HBV Negative 0 
23 AFB23 41 M HBV Positive 249.1 
24 AFB24 50 M HBV Negative 0 
25 AFB25 56 F HBV Negative 0 
26 AFB26 45 M HBV Negative 0 
27 AFB27 49 M HBV Positive 393.4 
28 AFB28 59 F HBV Negative 0 
29 AFB29 42 M HBV Negative 0 
30 AFB30 44 F HBV Positive 153.1 
31 AFB31 57 M HBV Negative 0 
32 AFB32 51 M HBV Negative 0 
33 AFB33 44 M HBV Negative 0 
34 AFB34 49 F HBV Negative 0 
35 AFB35 52 F HBV Negative 0 
36 AFB36 41 M HBV Negative 0 
37 AFB37 50 M HBV Positive 208.4 
38 AFB38 59 F HBV Negative 0 
39 AFB39 52 M HBV Positive 68.7 
40 AFB40 56 M HBV Negative 0 
41 AFB41 55 M HBV Negative 0 
42 AFB42 45 M HBV Negative 0 
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S.No Patient 
ID 
Age Gender Diagnosis Aflatoxin 
B1-lysine 
status 
AFB1 concentration in 
pg/mg of albumin 
43 AFB43 58 M HBV Positive 597.5 
44 AFB44 49 M HBV Negative 0 
45 AFB45 42 M HBV Negative 0 
46 AFB46 40 F HBV Negative 0 
47 AFB47 44 M HBV Positive 164.6 
48 AFB48 50 M HBV Negative 0 
49 AFB49 39 F HBV Negative 0 
50 AFB50 57 F HBV Negative 0 
51 AFB51 41 M HBV Negative 0 
52 AFB52 45 F HBV Positive 318.2 
53 AFB53 49 M HBV Negative 0 
54 AFB54 58 M HBV Negative 0 
55 AFB55 47 F HBV Negative 0 
56 AFB56 42 M HBV Negative 0 
57 AFB57 59 F HBV Negative 0 
58 AFB58 46 M HBV Negative 0 
59 AFB59 48 F HBV Negative 0 
60 AFB60 40 F HBV Negative 0 
61 AFB61 53 M HBV Negative 0 
62 AFB62 50 M HBV Negative 0 
63 AFB63 45 F HBV Negative 0 
64 AFB64 50 M HBV Negative 0 
65 AFB65 46 M HBV Negative 0 
66 AFB66 49 F HBV Negative 0 
67 AFB67 41 M HBV Negative 0 
68 AFB68 48 M HBV Positive 54.5 
69 AFB69 35 F HBV Negative 0 
70 AFB70 46 M HBV Negative 0 
71 AFB71 48 M HBV Negative 0 
72 AFB72 40 M HBV Positive 26 
73 AFB73 46 F HBV Negative 0 
74 AFB74 47 M HBV Negative 0 
75 AFB75 47 M HBV Positive 58.5 
76 AFB76 46 F HBV Negative 0 
77 AFB77 45 M HBV Negative 0 
78 AFB78 56 M HBV Negative 0 
79 AFB79 52 F HBV Negative 0 
80 AFB80 59 M HBV Positive 27.5 
81 AFB81 46 F HBV Negative 0 
82 AFB82 48 M HBV Negative 0 
83 AFB83 40 M HBV Negative 0 
84 AFB84 55 M HBV Positive 32.9 
85 AFB85 42 F HBV Negative 0 
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86 AFB86 55 M HBV Negative 0 
87 AFB87 54 M HBV Negative 0 
88 AFB88 59 F HBV Positive 115.1 
89 AFB89 49 M HBV Negative 0 
90 AFB90 46 M HBV Negative 0 
91 AFB91 49 F HBV Negative 0 
92 AFB92 58 M HBV Positive 186.2 
93 AFB93 45 F HBV Negative 0 
94 AFB94 57 M HBV Negative 0 
95 AFB95 53 M HBV Negative 0 
96 AFB96 48 F HBV Negative 0 
97 AFB97 40 M HBV Positive 30.7 
98 AFB98 49 F HBV Negative 0 
99 AFB99 53 M HBV Negative 0 
100 AFB100 47 M HBV Negative 0 
101 AFB101 54 M HBV Negative 0 
102 AFB102 45 M HBV Negative 0 
103 AFB103 41 M HBV Negative 0 
104 AFB104 54 F HBV Negative 0 
105 AFB105 46 M HBV Negative 0 
106 AFB106 53 F HBV Positive 121.4 
107 AFB107 49 M HBV Negative 0 
108 AFB108 45 F HBV Negative 0 
109 AFB109 47 M HBV Negative 0 
110 AFB110 45 F HBV Negative 0 
111 AFB111 48 M HBV Positive 73.3 
112 AFB112 51 M HBV Negative 0 
113 AFB113 49 M HBV Negative 0 
114 AFB114 56 M HBV Negative 0 
115 AFB115 53 F HBV Negative 0 
116 AFB116 46 M HBV Negative 0 
117 AFB117 52 M HBV Negative 0 
118 AFB118 43 M HBV Positive 83.7 
119 AFB119 41 M HBV Negative 0 
120 AFB120 56 M HBV Negative 0 
121 AFB121 45 M HBV Positive 119.4 
122 AFB122 49 M HBV Positive 169.7 
123 AFB123 39 M HBV Negative 0 
124 AFB124 47 M HBV Negative 0 
125 AFB125 58 F HBV Negative 0 
126 AFB126 53 F HBV Positive 129.5 
127 AFB127 61 M HBV Negative 0 
128 AFB128 56 F HBV Negative 0 
 156
S.No Patient 
ID 
Age Gender Diagnosis Aflatoxin 
B1-lysine 
status 
AFB1 concentration in 
pg/mg of albumin 
129 AFB129 59 M HBV Negative 0 
130 AFB130 44 M HBV Positive 114.2 
131 AFB131 29 M HBV Negative 0 
132 AFB132 40 M HBV Negative 0 
133 AFB133 43 M HBV Negative 0 
134 AFB134 60 M HBV Negative 0 
135 AFB135 76 M HBV Negative 0 
136 AFB136 35 F HBV Positive 132 
137 AFB137 65 M HBV Negative 0 
138 AFB138 53 M HBV Negative 0 
139 AFB139 44 M HBV Negative 0 
140 AFB140 32 M HBV Negative 0 
141 AFB141 38 M HBV Negative 0 
142 AFB142 42 M HBV Positive 57.5 
143 AFB143 32 M HBV Negative 0 
144 AFB144 51 M HBV Negative 0 
145 AFB145 57 M HBV Negative 0 
146 AFB146 60 M HBV Negative 0 
147 AFB147 55 M HBV Negative 0 
148 AFB148 55 M HBV Positive 38 
149 AFB149 18 M HBV Negative 0 
150 AFB150 65 M HBV Negative 0 
151 AFB151 62 M HBV Positive 110 
152 AFB152 48 F HBV Negative 0 
153 AFB153 51 M HBV Negative 0 
154 AFB154 50 M HBV Negative 0 
155 AFB155 49 F HBV Negative 0 
156 AFB156 52 M HBV Positive 33.75 
157 AFB157 68 M HBV Negative 0 
158 AFB158 54 M HBV Negative  
159 AFB159 74 M HBV Negative 0 
160 AFB160 60 M HBV Positive 185.85 
161 AFB161 59 M HBV Negative 0 
162 AFB162 49 F HBV Positive 43.1 
163 AFB163 58 F HBV Negative 0 
164 AFB164 52 M HBV Negative 0 
165 AFB165 48 F HBV Negative 0 
166 AFB166 55 M HBV Negative 0 
167 AFB167 53 M HBV Negative 0 
168 AFB168 45 M HBV Negative 0 
169 AFB169 43 M HBV Negative 0 
170 AFB170 47 F HBV Negative 0 
171 AFB171 56 M HBV Negative 0 
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172 AFB172 52 M HBV Negative 0 
173 AFB173 61 M HBV Negative 0 
174 AFB174 45 M HBV Negative 0 
175 AFB175 47 M HBV Negative 0 
176 AFB176 49 M HBV Negative 0 
177 AFB177 58 M HBV Positive 118.4 
178 AFB178 49 M HBV Negative 0.0 
179 AFB179 53 M HBV Positive 250.6 
180 AFB180 56 M HBV Negative 0.0 
181 AFB181 48 M HBV Positive 116.0 
182 AFB182 41 M HBV Negative 0.0 
183 AFB183 58 F HBV Positive 547.0 
184 AFB184 48 M HBV Negative 0.0 
185 AFB185 56 M HBV Negative 0.0 
186 AFB186 50 M HBV Negative 0.0 
187 AFB187 40 M HBV Positive 466.5 
188 AFB188 49 M HBV Negative 0.0 
189 AFB189 61 M HBV Negative 0.0 
190 AFB190 41 M HBV Negative 0.0 
191 AFB191 50 M HBV Negative 0.0 
192 AFB192 56 M HBV Negative 0.0 
193 AFB193 45 F HBV Negative 0.0 
194 AFB194 49 M HBV Positive 117.1 
195 AFB195 59 M HBV Negative 0.0 
196 AFB196 42 F HBV Negative 0.0 
197 AFB197 44 M HBV Negative 0.0 
198 AFB198 57 M HBV Negative 0.0 
199 AFB199 51 F HBV Negative 0.0 
200 AFB200 44 M HBV Negative 0.0 
201 AFB201 49 F HBV Negative 0.0 
202 AFB202 52 M HBV Negative 0.0 
203 AFB203 41 F HBV Negative 0.0 
204 AFB204 50 M HBV Negative 0.0 
205 AFB205 59 M HBV Negative 0.0 
206 AFB206 52 M HBV Negative 0.0 
207 AFB207 56 M HBV Negative 0.0 
208 AFB208 55 M HBV Negative 0.0 
209 AFB209 45 M HBV Positive 419.5 
210 AFB210 58 M HBV Negative 0.0 
211 AFB211 49 M HBV Negative 0.0 
212 AFB212 42 F HBV Negative 0.0 
213 AFB213 40 F HBV Negative 0.0 
214 AFB214 44 M HBV Negative 0.0 
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215 AFB215 50 M HBV Negative 0.0 
216 AFB216 39 M HBV Negative 0.0 
217 AFB217 57 F HBV Negative 0.0 
218 AFB218 41 M HBV Negative 0.0 
219 AFB219 45 F HBV Negative 0.0 
220 AFB220 49 M HBV Negative 0.0 
221 AFB221 58 M HBV Negative 0.0 
222 AFB222 47 M HBV Positive 394.5 
223 AFB223 42 M HBV Negative 0.0 
224 AFB224 59 F HBV Negative 0.0 
225 AFB225 46 F HBV Negative 0.0 
226 AFB226 48 F HBV Negative 0.0 
227 AFB227 40 F HBV Negative 0.0 
228 AFB228 53 M HBV Negative 0.0 
229 AFB229 50 F HBV Negative 0.0 
230 AFB230 45 M HBV Negative 0.0 
231 AFB231 50 M HBV Negative 0.0 
232 AFB232 46 M HBV Negative 0.0 
233 AFB233 49 M HBV Positive 257.0 
234 AFB234 41 M HBV Negative 0.0 
235 AFB235 48 F HBV Negative 0.0 
236 AFB236 35 M HBV Negative 0.0 
237 AFB237 46 M HBV Negative 0.0 
238 AFB238 48 M HBV Negative 0.0 
239 AFB239 40 M HBV Negative 0.0 
240 AFB240 46 M HBV Negative 0.0 
241 AFB241 47 M HBV Positive 438.0 
242 AFB242 47 M HBV Negative 0.0 
243 AFB243 46 M HBV Negative 0.0 
244 AFB244 45 M HBV Negative 0.0 
245 AFB245 56 F HBV Negative 0.0 
246 AFB246 52 F HBV Negative 0.0 
247 AFB247 59 M HBV Negative 0.0 
248 AFB248 46 M HBV Negative 0.0 
249 AFB249 48 M HBV Negative 0.0 
250 AFB250 40 M HBV Negative 0.0 
251 AFB251 55 M HBV Positive 27.5 
252 AFB252 42 M HBV Negative 0.0 
253 AFB253 55 F HBV Negative 0.0 
254 AFB254 54 M HBV Negative 0.0 
255 AFB255 59 F HBV Negative 0.0 
256 AFB256 49 M HBV Negative 0.0 
257 AFB257 46 F HBV Negative 0.0 
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258 AFB258 49 F HBV Negative 0.0 
259 AFB259 58 M HBV Negative 0.0 
260 AFB260 45 M HBV Negative 0.0 
261 AFB261 57 M HBV Negative 0.0 
262 AFB262 53 M HBV Negative 0.0 
263 AFB263 48 M HBV Negative 0.0 
264 AFB264 40 F HBV Negative 0.0 
265 AFB265 49 F HBV Negative 0.0 
266 AFB266 53 M HBV Negative 0.0 
267 AFB267 47 M HBV Negative 0.0 
268 AFB268 54 M HBV Negative 0.0 
269 AFB269 45 F HBV Positive 33.0 
270 AFB270 41 M HBV Negative 0.0 
271 AFB271 54 F HBV Negative 0.0 
272 AFB272 46 F HBV Negative 0.0 
273 AFB273 53 F HBV Negative 0.0 
274 AFB274 49 F HBV Negative 0.0 
275 AFB275 45 M HBV Negative 0.0 
276 AFB276 47 F HBV Negative 0.0 
277 AFB277 45 M HBV Negative 0.0 
278 AFB278 48 M HBV Negative 0.0 
279 AFB279 51 M HBV Negative 0.0 
280 AFB280 49 M HBV Negative 0.0 
281 AFB281 56 M HBV Negative 0.0 
282 AFB282 53 M HBV Positive 330.0 
283 AFB283 46 M HBV Negative 0.0 
284 AFB284 52 M HBV Negative 0.0 
285 AFB285 43 M HBV Negative 0.0 
286 AFB286 41 M HBV Negative 0.0 
287 AFB287 56 M HBV Negative 0.0 
288 AFB288 45 M HBV Negative 0.0 
289 AFB289 49 M HBV Negative 0.0 
290 AFB290 50 F HBV Negative 0.0 
291 AFB291 52 M HBV Positive 121.5 
292 AFB292 49 F HBV Negative 0.0 
293 AFB293 51 F HBV Negative 0.0 
294 AFB294 47 M HBV Negative 0.0 
295 AFB295 44 F HBV Negative 0.0 
296 AFB296 49 M HBV Negative 0.0 
297 AFB297 50 M HBV Negative 0.0 
298 AFB298 46 M HBV Positive 603.5 
299 AFB299 53 F HBV Positive 286.0 
300 AFB300 47 M HBV Negative 0.0 
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301 AFB301 55 F HBV Negative 0.0 
302 AFB302 48 M HBV Negative 0.0 
303 AFB303 43 F HBV Negative 0.0 
304 AFB304 52 M HBV Negative 0.0 
305 AFB305 41 M HBV Negative 0.0 
306 AFB306 44 F HBV Negative 0.0 
307 AFB307 58 M HBV Negative 0.0 
308 AFB308 56 M HBV Positive 42.0 
309 AFB309 53 M HBV Negative 0.0 
310 AFB310 52 M HBV Positive 229.0 
311 AFB311 58 M HBV Negative 0.0 
312 AFB312 47 M HBV Negative 0.0 
313 AFB313 49 F HBV Negative 0.0 
314 AFB314 52 F HBV Positive 19.5 
315 AFB315 50 M HBV Negative 0.0 
316 AFB316 49 M HBV Negative 0.0 
317 AFB317 46 F HBV Negative 0.0 
318 AFB318 42 M HBV Negative 0.0 
319 AFB319 51 F HBV Negative 0.0 
320 AFB320 54 M HBV Negative 0.0 
321 AFB321 47 F HBV Positive 343.0 
322 AFB322 56 F HBV Negative 0.0 
323 AFB323 58 F HBV Negative 0.0 
324 AFB324 43 F HBV Negative 0.0 
325 AFB325 46 F HBV Negative 0.0 
326 AFB326 49 F HBV Positive 36.5 
327 AFB327 52 F HBV Negative 0.0 
328 AFB328 44 M HBV Positive 450.0 
329 AFB329 53 M HBV Negative 0.0 
330 AFB330 58 M HBV Negative 0.0 
331 AFB331 49 M HBV Negative 0.0 
332 AFB332 58 M HBV Negative 0.0 
333 AFB333 43 M HBV Positive 79.5 
334 AFB334 49 F HBV Negative 0.0 
335 AFB335 51 F HBV Negative 0.0 
336 AFB336 54 M HBV Negative 0.0 
337 AFB337 44 M HBV Positive 25.5 
338 AFB338 48 M HBV Negative 0.0 
339 AFB339 55 M HBV Negative 0.0 
340 AFB340 47 M HBV Negative 0.0 
341 AFB341 39 F HBV Negative 0.0 
342 AFB342 46 M HBV Negative 0.0 
343 AFB343 47 F HBV Negative 0.0 
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344 AFB344 52 F HBV Negative 0.0 
345 AFB345 46 M HBV Negative 0.0 
346 AFB346 41 F HBV Positive 57.5 
347 AFB347 43 F HBV Positive 29.5 
348 AFB348 56 F HBV Positive 76.0 
349 AFB349 50 F HBV Negative 0.0 
350 AFB350 44 M HBV Negative 0.0 
351 AFB351 52 M HBV Negative 0.0 
352 AFB352 40 M HBV Negative 0.0 
353 AFB353 42 M HBV Negative 0.0 
354 AFB354 53 M HBV Negative 0.0 
355 AFB355 49 F HBV Negative 0.0 
356 AFB356 43 M HBV Positive 438.0 
357 AFB357 45 M HBV Negative 0.0 
358 AFB358 42 M HBV Negative 0.0 
359 AFB359 52 M HBV Negative 0.0 
360 AFB360 40 F HBV Positive 622.5 
361 AFB361 46 F HBV Negative 0.0 
362 AFB362 43 M HBV Negative 0.0 
363 AFB363 48 F HBV Negative 0.0 
364 AFB364 52 M HBV Negative 0.0 
365 AFB365 41 M HBV Positive 283.5 
366 AFB366 58 M HBV Negative 0.0 
367 AFB367 48 M HBV Negative 0.0 
368 AFB368 46 F HBV Negative 0.0 
369 AFB369 51 F HBV Negative 0.0 
370 AFB370 46 M HBV Negative 0.0 
371 AFB371 49 F HBV Negative 0.0 
372 AFB372 47 M HBV Negative 0.0 
373 AFB373 46 M HBV Positive 617.5 
374 AFB374 36 M HBV Negative 0.0 
375 AFB375 53 F HBV Negative 0.0 
376 AFB376 42 F HBV Negative 0.0 
377 AFB377 57 M HBV Negative 0.0 
378 AFB378 44 M HBV Positive 234.0 
379 AFB379 50 M HBV Negative 0.0 
380 AFB380 56 M HBV Negative 0.0 
381 AFB381 44 F Control Negative 0.0 
382 AFB382 49 M Control Negative 0.0 
383 AFB383 46 F Control Negative 0.0 
384 AFB384 41 M Control Negative 0.0 
385 AFB385 43 M Control Negative 0.0 
386 AFB386 59 F Control Negative 0.0 
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387 AFB387 45 M Control Negative 0.0 
388 AFB388 52 M Control Negative 0.0 
389 AFB389 43 F Control Negative 0.0 
390 AFB390 49 M Control Negative 0.0 
391 AFB391 50 F Control Negative 0.0 
392 AFB392 52 M Control Negative 0.0 
393 AFB393 49 M Control Negative 0.0 
394 AFB394 51 M Control Negative 0.0 
395 AFB395 47 F Control Negative 0.0 
396 AFB396 44 F Control Negative 0.0 
397 AFB397 49 M Control Negative 0.0 
398 AFB398 50 M Control Negative 0.0 
399 AFB399 46 F Control Negative 0.0 
400 AFB400 53 M Control Negative 0.0 
401 AFB401 47 M Control Negative 0.0 
402 AFB402 55 M Control Negative 0.0 
403 AFB403 48 M Control Negative 0.0 
404 AFB404 43 F Control Negative 0.0 
405 AFB405 52 M Control Negative 0.0 
406 AFB406 41 F Control Negative 0.0 
407 AFB407 44 F Control Negative 0.0 
408 AFB408 58 M Control Negative 0.0 
409 AFB409 56 M Control Negative 0.0 
410 AFB410 53 M Control Negative 0.0 
411 AFB411 52 F Control Negative 0.0 
412 AFB412 58 M Control Negative 0.0 
413 AFB413 47 M Control Negative 0.0 
414 AFB414 49 M Control Negative 0.0 
415 AFB415 52 M Control Negative 0.0 
416 AFB416 50 M Control Negative 0.0 
417 AFB417 49 F Control Positive 322.5 
418 AFB418 46 F Control Negative 0.0 
419 AFB419 42 M Control Negative 0.0 
420 AFB420 51 M Control Negative 0.0 
421 AFB421 54 M Control Negative 0.0 
422 AFB422 47 F Control Negative 0.0 
423 AFB423 56 F Control Negative 0.0 
424 AFB424 58 M Control Positive 41.0 
425 AFB425 43 F Control Negative 0.0 
426 AFB426 46 M Control Negative 0.0 
427 AFB427 49 F Control Negative 0.0 
428 AFB428 52 M Control Negative 0.0 
429 AFB429 44 F Control Negative 0.0 
 163
S.No Patient 
ID 
Age Gender Diagnosis Aflatoxin 
B1-lysine 
status 
AFB1 concentration in 
pg/mg of albumin 
430 AFB430 53 F Control Negative 0.0 
431 AFB431 58 M Control Negative 0.0 
432 AFB432 49 M Control Negative 0.0 
433 AFB433 58 M Control Negative 0.0 
434 AFB434 43 M Control Negative 0.0 
435 AFB435 49 F Control Negative 0.0 
436 AFB436 51 M Control Negative 0.0 
437 AFB437 54 M Control Negative 0.0 
438 AFB438 44 M Control Negative 0.0 
439 AFB439 48 M Control Negative 0.0 
440 AFB440 55 F Control Negative 0.0 
441 AFB441 47 F Control Negative 0.0 
442 AFB442 39 M Control Negative 0.0 
443 AFB443 46 F Control Negative 0.0 
444 AFB444 47 M Control Positive 52.5 
445 AFB445 52 M Control Negative 0.0 
446 AFB446 46 M Control Negative 0.0 
447 AFB447 41 M Control Negative 0.0 
448 AFB448 43 F Control Negative 0.0 
449 AFB449 56 F Control Negative 0.0 
450 AFB450 50 M Control Negative 0.0 
451 AFB451 44 F Control Negative 0.0 
452 AFB452 52 M Control Negative 0.0 
453 AFB453 40 M Control Negative 0.0 
454 AFB454 42 M Control Negative 0.0 
455 AFB455 53 F Control Positive 74.1 
456 AFB456 49 F Control Negative 0.0 
457 AFB457 43 M Control Negative 0.0 
458 AFB458 45 M Control Negative 0.0 
459 AFB459 42 M Control Negative 0.0 
460 AFB460 52 M Control Negative 0.0 
461 AFB461 40 F Control Negative 0.0 
462 AFB462 46 M Control Negative 0.0 
463 AFB463 43 M Control Negative 0.0 
464 AFB464 48 M Control Negative 0.0 
465 AFB465 52 M Control Negative 0.0 
466 AFB466 41 F Control Positive 2.8 
467 AFB467 58 M Control Negative 0.0 
468 AFB468 48 M Control Negative 0.0 
469 AFB469 46 F Control Negative 0.0 
470 AFB470 51 M Control Negative 0.0 
471 AFB471 46 M Control Negative 0.0 
472 AFB472 49 M Control Negative 0.0 
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473 AFB473 47 M Control Negative 0.0 
474 AFB474 46 M Control Negative 0.0 
475 AFB475 36 F Control Negative 0.0 
476 AFB476 53 M Control Negative 0.0 
477 AFB477 42 F Control Negative 0.0 
478 AFB478 57 M Control Negative 0.0 
479 AFB479 44 F Control Negative 0.0 
480 AFB480 50 M Control Negative 0.0 
481 AFB481 56 F Control Negative 0.0 
482 AFB482 44 M Control Negative 0.0 
483 AFB483 49 F Control Negative 0.0 
484 AFB484 46 M Control Negative 0.0 
485 AFB485 41 M Control Negative 0.0 
486 AFB486 43 F Control Negative 0.0 
487 AFB487 59 M Control Negative 0.0 
488 AFB488 45 M Control Positive 593.5 
489 AFB489 52 F Control Negative 0.0 
490 AFB490 43 M Control Negative 0.0 
491 AFB491 49 F Control Negative 0.0 
492 AFB492 50 M Control Negative 0.0 
493 AFB493 52 M Control Negative 0.0 
494 AFB494 49 M Control Negative 0.0 
495 AFB495 51 F Control Negative 0.0 
496 AFB496 47 F Control Negative 0.0 
497 AFB497 44 M Control Positive 41.0 
498 AFB498 49 M Control Negative 0.0 
499 AFB499 50 F Control Negative 0.0 
500 AFB500 46 M Control Negative 0.0 
501 AFB501 53 M Control Negative 0.0 
502 AFB502 47 M Control Negative 0.0 
503 AFB503 55 M Control Negative 0.0 
504 AFB504 48 M Control Positive 25.0 
505 AFB505 43 M Control Negative 0.0 
506 AFB506 52 M Control Negative 0.0 
507 AFB507 41 F Control Negative 0.0 
508 AFB508 44 M Control Negative 0.0 
509 AFB509 58 M Control Negative 0.0 
510 AFB510 56 F Control Negative 0.0 
511 AFB511 53 F Control Positive 49.0 
512 AFB512 52 M Control Negative 0.0 
513 AFB513 58 F Control Negative 0.0 
514 AFB514 47 F Control Negative 0.0 
515 AFB515 49 M Control Negative 0.0 
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516 AFB516 52 M Control Negative 0.0 
517 AFB517 50 M Control Negative 0.0 
518 AFB518 49 M Control Negative 0.0 
519 AFB519 46 F Control Negative 0.0 
520 AFB520 42 M Control Negative 0.0 
521 AFB521 51 F Control Negative 0.0 
522 AFB522 54 M Control Negative 0.0 
523 AFB523 47 F Control Negative 0.0 
524 AFB524 56 M Control Negative 0.0 
525 AFB525 58 F Control Negative 0.0 
526 AFB526 43 M Control Negative 0.0 
527 AFB527 46 F Control Negative 0.0 
528 AFB528 49 M Control Negative 0.0 
529 AFB529 52 F Control Negative 0.0 
530 AFB530 44 M Control Negative 0.0 
531 AFB531 53 M Control Negative 0.0 
532 AFB532 58 F Control Negative 0.0 
533 AFB533 49 F Control Negative 0.0 
534 AFB534 58 M Control Negative 0.0 
535 AFB535 43 M Control Negative 0.0 
536 AFB536 49 F Control Negative 0.0 
537 AFB537 51 M Control Negative 0.0 
538 AFB538 54 F Control Negative 0.0 
539 AFB539 44 M Control Negative 0.0 
540 AFB540 48 M Control Negative 0.0 
541 AFB541 55 M Control Negative 0.0 
542 AFB542 47 M Control Negative 0.0 
543 AFB543 39 M Control Negative 0.0 
544 AFB544 46 M Control Negative 0.0 
545 AFB545 47 M Control Negative 0.0 
546 AFB546 52 F Control Negative 0.0 
547 AFB547 46 F Control Negative 0.0 
548 AFB548 41 M Control Negative 0.0 
549 AFB549 43 F Control Negative 0.0 
550 AFB550 56 M Control Negative 0.0 
551 AFB551 50 M Control Negative 0.0 
552 AFB552 44 M Control Negative 0.0 
553 AFB553 52 M Control Negative 0.0 
554 AFB554 40 F Control Negative 0.0 
555 AFB555 42 F Control Negative 0.0 
556 AFB556 53 M Control Negative 0.0 
557 AFB557 49 M Control Negative 0.0 
558 AFB558 43 M Control Negative 0.0 
 166
S.No Patient 
ID 
Age Gender Diagnosis Aflatoxin 
B1-lysine 
status 
AFB1 concentration in 
pg/mg of albumin 
559 AFB559 45 M Control Negative 0.0 
560 AFB560 42 M Control Negative 0.0 
561 AFB561 52 M Control Negative 0.0 
562 AFB562 40 M Control Negative 0.0 
563 AFB563 46 M Control Negative 0.0 
564 AFB564 43 M Control Negative 0.0 
565 AFB565 48 M Control Negative 0.0 
566 AFB566 52 M Control Negative 0 
567 AFB567 41 F Control Negative 0 
568 AFB568 58 M Control Negative 0 
569 AFB569 48 M Control Negative 0 
570 AFB570 46 M Control Negative 0 
571 AFB571 51 F Control Negative 0 
572 AFB572 46 F Control Negative 0 
573 AFB573 49 M Control Positive 14 
574 AFB574 47 F Control Negative 0 
575 AFB575 46 M Control Negative 0 
576 AFB576 36 F Control Negative 0 
577 AFB577 53 M Control Negative 0 
578 AFB578 42 F Control Negative 0 
579 AFB579 57 M Control Negative 0 
580 AFB580 44 M Control Negative 0 
581 AFB581 50 M Control Negative 0 
582 AFB582 56 M Control Negative 0 
583 AFB583 44 F Control Negative 0 
584 AFB584 49 M Control Negative 0 
585 AFB585 46 F Control Negative 0 
586 AFB586 41 M Control Negative 0 
587 AFB587 43 F Control Negative 0 
588 AFB588 59 M Control Negative 0 
589 AFB589 45 M Control Negative 0 
590 AFB590 52 M Control Negative 0 
591 AFB591 43 F Control Negative 0 
592 AFB592 56 M Control Negative 0 
593 AFB593 53 F Control Negative 0 
594 AFB594 52 M Control Negative 0 
595 AFB595 58 M Control Negative 0 
596 AFB596 47 F Control Negative 0 
597 AFB597 49 F Control Negative 0 
598 AFB598 52 M Control Negative 0 
599 AFB599 50 F Control Negative 0 
600 AFB600 49 F Control Negative 0 
601 AFB601 46 M Control Negative 0 
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602 AFB602 42 F Control Negative 0 
603 AFB603 51 M Control Negative 0 
604 AFB604 54 M Control Negative 0 
605 AFB605 47 F Control Negative 0 
606 AFB606 56 M Control Negative 0 
607 AFB607 58 F Control Negative 0 
608 AFB608 43 F Control Negative 0 
609 AFB609 46 M Control Negative 0 
610 AFB610 49 M Control Negative 0 
611 AFB611 52 F Control Negative 0 
612 AFB612 44 M Control Negative 0 
613 AFB613 53 F Control Negative 0 
614 AFB614 58 M Control Positive 9.1 
615 AFB615 49 M Control Negative 0 
616 AFB616 58 M Control Negative 0 
617 AFB617 43 F Control Negative 0 
618 AFB618 49 M Control Negative 0 
619 AFB619 51 F Control Negative 0 
620 AFB620 54 F Control Negative 0 
621 AFB621 44 M Control Negative 0 
622 AFB622 48 M Control Negative 0 
623 AFB623 55 M Control Negative 0 
624 AFB624 47 M Control Positive 77.2 
625 AFB625 39 F Control Negative 0 
626 AFB626 46 M Control Negative 0 
627 AFB627 47 F Control Negative 0 
628 AFB628 52 M Control Negative 0 
629 AFB629 46 F Control Negative 0 
630 AFB630 41 M Control Negative 0 
631 AFB631 43 F Control Negative 0 
632 AFB632 56 M Control Negative 0 
633 AFB633 50 F Control Negative 0 
634 AFB634 44 M Control Negative 0 
635 AFB635 52 F Control Negative 0 
636 AFB636 40 M Control Negative 0 
637 AFB637 42 M Control Negative 0 
638 AFB638 53 F Control Negative 0 
639 AFB639 49 F Control Negative 0 
640 AFB640 43 M Control Negative 0 
641 AFB641 45 M Control Negative 0 
642 AFB642 42 F Control Negative 0 
643 AFB643 52 M Control Negative 0 
644 AFB644 40 F Control Negative 0 
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645 AFB645 46 M Control Negative 0 
646 AFB646 43 M Control Positive 34.5 
647 AFB647 48 M Control Negative 0 
648 AFB648 52 M Control Negative 0 
649 AFB649 41 M Control Negative 0 
650 AFB650 58 M Control Negative 0 
651 AFB651 48 M Control Negative 0 
652 AFB652 46 F Control Negative 0 
653 AFB653 51 F Control Positive 114.6 
654 AFB654 46 M Control Negative 0 
655 AFB655 49 F Control Negative 0 
656 AFB656 47 M Control Negative 0 
657 AFB657 46 M Control Negative 0 
658 AFB658 36 M Control Positive 112.5 
659 AFB659 53 M Control Positive 91.7 
660 AFB660 42 F Control Negative 0 
661 AFB661 57 F Control Negative 0 
662 AFB662 44 M Control Negative 0 
663 AFB663 50 F Control Negative 0 
664 AFB664 56 M Control Negative 0 
665 AFB665 44 M Control Negative 0 
666 AFB666 49 M Control Positive 90.5 
667 AFB667 46 F Control Negative 0 
668 AFB668 41 F Control Negative 0 
669 AFB669 43 M Control Negative 0 
670 AFB670 59 M Control Negative 0 
671 AFB671 45 M Control Negative 0 
672 AFB672 52 M Control Positive 159.6 
673 AFB673 43 F Control Negative 0 
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Chart 2: P53 mutation positive status in hepatitis B positive and control samples 
S.No Age Gender Hepatitis 
B 
Aflatoxin 
B1 
P53 
Mutation 
AFB1 concentration 
in pg/mg of albumin 
1 45 M Positive Positive Negative 31.5 
2 43 M Positive Negative Negative 0 
3 47 M Positive Negative Negative 0 
4 56 M Positive Positive Negative 129 
5 52 F Positive Negative Negative 0 
6 61 M Positive Negative Negative 0 
7 45 M Positive Positive Negative 111 
8 47 F Positive Negative Negative 0 
9 49 M Positive Negative Negative 0 
10 58 M Positive Positive Positive 676.5 
11 49 M Positive Negative Negative 0 
12 53 M Positive Negative Negative 0 
13 56 M Positive Negative Negative 0 
14 48 F Positive Negative Negative 0 
15 41 M Positive Negative Negative 0 
16 58 F Positive Negative Negative 0 
17 48 M Positive Positive Negative 403.0 
18 56 F Positive Negative Negative 0 
19 50 M Positive Positive Negative 180.0 
20 40 F Positive Negative Negative 0 
21 49 M Positive Negative Negative 0 
22 61 F Positive Negative Negative 0 
23 41 M Positive Positive Negative 249.1 
24 50 M Positive Negative Negative 0 
25 56 F Positive Negative Negative 0 
26 45 M Positive Negative Negative 0 
27 49 M Positive Positive Positive 393.4 
28 59 F Positive Negative Negative 0 
29 42 M Positive Negative Negative 0 
30 44 F Positive Positive Negative 153.1 
31 57 M Positive Negative Negative 0 
32 51 M Positive Negative Negative 0 
33 44 M Positive Negative Negative 0 
34 49 F Positive Negative Negative 0 
35 52 F Positive Negative Negative 0 
36 41 M Positive Negative Negative 0 
37 50 M Positive Positive Negative 208.4 
38 59 F Positive Negative Negative 0 
39 52 M Positive Positive Negative 68.7 
40 56 M Positive Negative Negative 0 
41 55 M Positive Negative Negative 0 
42 45 M Positive Negative Negative 0 
43 58 M Positive Positive Positive 597.5 
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S.No Age Gender Hepatitis 
B 
Aflatoxin 
B1 
P53 
Mutation 
AFB1 concentration 
in pg/mg of albumin 
44 49 M Positive Negative Negative 0 
45 42 M Positive Negative Negative 0 
46 40 F Positive Negative Negative 0 
47 44 M Positive Positive Negative 164.6 
48 50 M Positive Negative Negative 0 
49 39 F Positive Negative Negative 0 
50 57 F Positive Negative Negative 0 
51 41 M Positive Negative Negative 0 
52 45 F Positive Positive Positive 318.2 
53 49 M Positive Negative Negative 0 
54 58 M Positive Negative Positive 0 
55 47 F Positive Negative Negative 0 
56 42 M Positive Negative Negative 0 
57 59 F Positive Negative Negative 0 
58 46 M Positive Negative Negative 0 
59 48 F Positive Negative Negative 0 
60 40 F Positive Negative Negative 0 
61 53 M Positive Negative Negative 0 
62 50 M Positive Negative Negative 0 
63 45 F Positive Negative Negative 0 
64 50 M Positive Negative Negative 0 
65 46 M Positive Negative Negative 0 
66 49 F Positive Negative Negative 0 
67 41 M Positive Negative Negative 0 
68 48 M Positive Positive Negative 54.5 
69 35 F Positive Negative Negative 0 
70 46 M Positive Negative Negative 0 
71 48 M Positive Negative Negative 0 
72 40 M Positive Positive Negative 26 
73 46 F Positive Negative Negative 0 
74 47 M Positive Negative Negative 0 
75 47 M Positive Positive Negative 58.5 
76 46 F Positive Negative Negative 0 
77 45 M Positive Negative Positive 0 
78 56 M Positive Negative Negative 0 
79 52 F Positive Negative Negative 0 
80 59 M Positive Positive Negative 27.5 
81 46 F Positive Negative Negative 0 
82 48 M Positive Negative Negative 0 
83 40 M Positive Negative Negative 0 
84 55 M Positive Positive Negative 32.9 
85 42 F Positive Negative Negative 0 
86 55 M Positive Negative Negative 0 
87 54 M Positive Negative Positive 0 
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S.No Age Gender Hepatitis 
B 
Aflatoxin 
B1 
P53 
Mutation 
AFB1 concentration 
in pg/mg of albumin 
88 59 F Positive Positive Negative 115.1 
89 49 M Positive Negative Negative 0 
90 46 M Positive Negative Negative 0 
91 49 F Positive Negative Negative 0 
92 58 M Positive Positive Negative 186.2 
93 45 F Positive Negative Negative 0 
94 57 M Positive Negative Negative 0 
95 53 M Positive Negative Negative 0 
96 48 F Positive Negative Negative 0 
97 40 M Positive Positive Negative 30.7 
98 49 F Positive Negative Negative 0 
99 53 M Positive Negative Negative 0 
100 47 M Positive Negative Negative 0 
101 54 M Positive Negative Negative 0 
102 45 M Positive Negative Negative 0 
103 41 M Positive Negative Negative 0 
104 54 F Positive Negative Negative 0 
105 46 M Positive Negative Negative 0 
106 53 F Positive Positive Negative 121.4 
107 49 M Positive Negative Negative 0 
108 45 F Positive Negative Negative 0 
109 47 M Positive Negative Negative 0 
110 45 F Positive Negative Negative 0 
111 48 M Positive Positive Negative 73.3 
112 51 M Positive Negative Negative 0 
113 49 M Positive Negative Negative 0 
114 56 M Positive Negative Negative 0 
115 53 F Positive Negative Negative 0 
116 46 M Positive Negative Negative 0 
117 52 M Positive Negative Positive 0 
118 43 M Positive Positive Negative 83.7 
119 41 M Positive Negative Negative 0 
120 56 M Positive Negative Negative 0 
121 45 M Positive Positive Negative 119.4 
122 49 M Positive Positive Negative 169.7 
123 39 M Positive Negative Negative 0 
124 47 M Positive Negative Negative 0 
125 58 F Positive Negative Negative 0 
126 53 F Positive Positive Negative 0 
127 61 M Positive Negative Negative 0 
128 56 F Positive Negative Negative 0 
129 59 M Positive Negative Negative 0 
130 44 M Positive Positive Negative 129.5 
131 55 M Negative Negative Negative 0 
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S.No Age Gender Hepatitis 
B 
Aflatoxin 
B1 
P53 
Mutation 
AFB1 concentration 
in pg/mg of albumin 
132 47 F Negative Negative Negative 0 
133 43 M Negative Negative Negative 0 
134 56 M Negative Negative Negative 0 
135 42 M Negative Negative Negative 0 
136 49 F Negative Negative Negative 0 
137 45 F Negative Negative Negative 0 
138 49 M Negative Negative Negative 0 
139 50 F Negative Negative Negative 0 
140 52 M Negative Negative Negative 0 
141 49 F Negative Negative Negative 0 
142 51 M Negative  Negative Negative 0 
143 47 F Negative Negative Negative 0 
144 44 M Negative Negative Negative 0 
145 49 M Negative Negative Negative 0 
146 50 M Negative Negative Negative 0 
147 46 M Negative Negative Negative 0 
148 53 F Negative Negative Negative 0 
149 47 M Negative Negative Negative 0 
150 55 F Negative Negative Negative 0 
151 48 M Negative Negative Negative 0 
152 43 F Negative Negative Negative 0 
153 52 M Negative Negative Negative 0 
154 41 M Negative Negative Negative 0 
155 44 M Negative Negative Negative 0 
156 58 F Negative Negative Negative 0 
157 56 M Negative Negative Negative 0 
158 53 F Negative Negative Negative 0 
159 52 M Negative Negative Negative 0 
160 58 M Negative Negative Negative 0 
161 47 F Negative Negative Negative 0 
162 49 F Negative Negative Negative 0 
163 52 M Negative Negative Negative 0 
164 50 F Negative Negative Negative 0 
165 49 F Negative Negative Negative 0 
166 46 M Negative Negative Negative 0 
167 42 F Negative Negative Negative 0 
168 51 M Negative Negative Negative 0 
169 54 M Negative Negative Positive 0 
170 47 F Negative Negative Negative 0 
171 56 M Negative Negative Negative 0 
172 58 F Negative Negative Negative 0 
173 43 F Negative Negative Negative 0 
174 46 M Negative Negative Negative 0 
175 49 M Negative Negative Negative 0 
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S.No Age Gender Hepatitis 
B 
Aflatoxin 
B1 
P53 
Mutation 
AFB1 concentration 
in pg/mg of albumin 
176 52 F Negative Negative Negative 0 
177 44 M Negative Negative Negative 0 
178 53 F Negative Negative Negative 0 
179 58 M Negative Positive Positive 9.1 
180 49 M Negative Negative Negative 0 
181 58 M Negative Negative Negative 0 
182 43 F Negative Negative Negative 0 
183 49 M Negative Negative Negative 0 
184 51 F Negative Negative Negative 0 
185 54 F Negative Negative Negative 0 
186 44 M Negative Negative Negative 0 
187 48 M Negative Negative Negative 0 
188 55 M Negative Negative Negative 0 
189 47 M Negative Positive Negative 77.2 
190 39 F Negative Negative Negative 0 
191 46 M Negative Negative Negative 0 
192 47 F Negative Negative Negative 0 
193 52 M Negative Negative Negative 0 
194 46 F Negative Negative Negative 0 
195 41 M Negative Negative Negative 0 
196 43 F Negative Negative Negative 0 
197 56 M Negative Negative Negative 0 
198 50 F Negative Negative Negative 0 
199 44 M Negative Negative Negative 0 
200 52 F Negative Negative Negative 0 
201 40 M Negative Negative Negative 0 
202 42 M Negative Negative Negative 0 
203 53 F Negative Negative Negative 0 
204 49 F Negative Negative Negative 0 
205 43 M Negative Negative Negative 0 
206 45 M Negative Negative Negative 0 
207 42 F Negative Negative Negative 0 
208 52 M Negative Negative Negative 0 
209 40 F Negative Negative Negative 0 
210 46 M Negative Negative Negative 0 
211 43 M Negative Positive Negative 34.5 
212 48 M Negative Negative Negative 0 
213 52 M Negative Negative Negative 0 
214 41 M Negative Negative Negative 0 
215 58 M Negative Negative Negative 0 
216 48 M Negative Negative Negative 0 
217 46 F Negative Negative Negative 0 
218 51 F Negative Positive Negative 114.6 
219 46 M Negative Negative Negative 0 
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S.No Age Gender Hepatitis 
B 
Aflatoxin 
B1 
P53 
Mutation 
AFB1 concentration 
in pg/mg of albumin 
220 49 F Negative Negative Negative 0 
221 47 M Negative Negative Negative 0 
222 46 M Negative Negative Negative 0 
223 36 M Negative Positive Negative 112.5 
224 53 M Negative Positive Negative 91.7 
225 42 F Negative Negative Negative 0 
226 57 F Negative Negative Negative 0 
227 44 M Negative Negative Negative 0 
228 50 F Negative Negative Negative 0 
229 56 M Negative Negative Negative 0 
230 44 M Negative Negative Negative 0 
231 49 M Negative Positive Negative 90.5 
232 46 F Negative Negative Negative 0 
233 41 F Negative Negative Negative 0 
234 43 M Negative Negative Negative 0 
235 59 M Negative Negative Negative 0 
236 45 M Negative Negative Negative 0 
237 52 M Negative Positive Negative 159.6 
238 43 F Negative Negative Negative 0 
 
 
 
 
 
